CUMULATIVE
SUPPLEMENT 11
JAN'90-NOV'90



APPROVED DRUG PRODUCTS

WITH THERAPEUTIC EQUIVALENCE EVALUATIONS

10TH EDITION

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
PUBLIC HEALTH SERVICE
FOOD AND DRUG ADMINISTRATION

Prepared By
Division of Drug Information Resources
Office of Management
Center for Drug Evaluation and Research, FDA

APPROVED DRUG PRODUCTS

with

THERAPEUTIC EQUIVALENCE EVALUATIONS

10TH EDITION

CUMULATIVE SUPPLEMENT 11

NOVEMBER 1990

CONTENTS

		PAGE
1.0	INTRODUCTION	iii
1.1	How to Use the Cumulative Supplement	iii
1.2	Products Requiring Revised Labeling for Full Approval	v
1.3	Applicant (Name) Changes	v
1.4	Report of Counts for the Prescription Drug Product List	vii
2.0	DRUG PRODUCT LISTS	
2.1	Prescription Drug Product List	1
2.2	OTC Drug Product List	34
2.3	Drug Products with Approval under Section 505 of the Act Administered by the Division of Blood and Blood Products List	35
2.4	Orphan Drug Product Designations	36
2.5	Drug Products Which Must Demonstrate in vivo Bioavailability Only if Product Fails to Achieve Adequate Dissolution	49
2.6	Biopharmaceutic Guidance Availability	50
2.7	ANDA Suitability Petitions	51
	PATENT AND EXCLUSIVITY INFORMATION ADDENDUM	
	A. Exclusivity Terms	54
	B. Patent and Exclusivity Lists	55

APPROVED DRUG PRODUCTS

with

THERAPEUTIC EQUIVALENCE EVALUATIONS

10th EDITION

CUMULATIVE SUPPLEMENT 11

NOVEMBER 1990

1.0 INTRODUCTION

1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 10th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations, over-the-counter (OTC) drug products that require approved applications as a condition of marketing, drug products with Approval under Section 505 of the Act administered by the Division of Blood and Blood Products and products discontinued from marketing or products which have had their approval withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Division of Blood and Blood Products lists.

The Patent and Exclusivity Lists are arranged in alphabetical order by active ingredient name. For those products with multiple active ingredients, only the first active ingredient (in alphabetical sort) will appear. In addition, the trade name will be displayed to the right of the active ingredient name for each product, along with the application number and product number (FDA's internal file number). All patents with their expiration dates are displayed for each application number. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms section in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to place an asterisk (*) to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement.

Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision. [Strength(s) which already exist in the List will not be repeated for context.] The effective date for the approved drug product (the earliest date a product may be marketed) appears, when appropriate, to the left of the approval date.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Additions new to the Prescription Drug Product List, OTC Drug Product List, Drug Products with Approval under Section 505 of the Act Administered by the Division of Blood and Blood Products List and the Patent and Exclusivity Data are indicated by the symbol **>ADD>** to the left of the line on which new information exists. The **>ADD>** symbol is then dropped in subsequent Cumulative Supplements for that item. A newly approved product is also identified by a lozenge (▪) to the right of its strength which remains throughout all Cumulative Supplements for this edition.

Deletions new to the Prescription Drug Product List, OTC Drug Product List, Drug Products with Approval under Section 505 of the Act Administered by the Division of Blood and Blood Products List and the Patent and Exclusivity Data are indicated by the symbol **>DLT>** (DELETE) to the left of the line containing overstruck print. The **>DLT>** symbol is dropped in subsequent Cumulative Supplements for that item. The overstruck print will remain in the Prescription Drug Product List and OTC Drug Product Lists in all Cumulative Supplements for this edition. However, the overstruck print in the Drug Products with Approval under Section 505 of the Act Administered by the Division of Blood and Blood Products List and the Patent and Exclusivity Data will be dropped in subsequent Cumulative Supplements.

Products discontinued from marketing or products which have had their approval withdrawn for other than safety or effectiveness reasons, will be flagged in this Cumulative Supplement with the "ə" symbol to designate their non-marketed status. All products having a "ə" symbol in the 12th Cumulative Supplement of the 10th Edition List will then be added to the "Discontinued Drug Product List" appearing in the 11th Edition.

1.2 PRODUCTS REQUIRING REVISED LABELING FOR FULL APPROVAL

Drug products in this category (1) initially received approval only on the basis of safety before effectiveness studies were required, or (2) were conditionally approved under the temporary exemption that allowed these products to be marketed while effectiveness studies were being conducted. Listed below are those drugs which are now required to revise their labeling and provide additional information necessary for full approval on the basis of requirements listed in the Federal Register. As approval is granted by the Agency for a specific product, based on additional information submitted by the applicant, the product will be included in the appropriate Drug Product List.

Products	Federal Register Reference
Nitroglycerin (capsule, controlled release;oral)	SEP 7, 1984 (49 FR 35428)
Nitroglycerin (tablet, controlled release;oral)	SEP 7, 1984 (49 FR 35428)
Nitroglycerin (tablet, controlled release;buccal)	JUL 5, 1985 (50 FR 27688)
Tranylcypromine Sulfate	MAR 22, 1984 (49 FR 10708)

1.3 APPLICANT (NAME) CHANGES

Because it is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name, the cumulation of these transfers and name changes will be identified in this section only. Where only partial approved product lines are transferred between applicants, each approved product involved will appear as an applicant name change in the Cumulative Supplement.

APPLICANT (NAME) CHANGES

FORMER APPLICANT (NAME)	NEW APPLICANT (NAME)	ABBREVIATED NAME
BOOTS COMPANY USA INC	BOOTS PHARMS INC	BOOTS PHARM
MERRELL DOW PHARMACEUTICALS INC SUB DOW CHEMCIAL CO	MERRRELL DOW PHARMS INC SUB MARION MERRELL DOW INC	MERRELL DOW PHARMS
MARION LABORATORIES INC	MARION MERRELL DOW INC	MARION MERRELL DOW
NORDISK INSULIN LABORATORIUM	NOVO NORDISK PHARMS INC	NOVO NORDISK PHARMS
NORDISK USA	NOVO NORDISK PHARMS INC	NOVO NORDISK PHARMS

APPLICANT (NAME) CHANGES

FORMER APPLICANT (NAME)	NEW APPLICANT (NAME)	ABBREVIATED NAME
PACO RESEARCH & DEVELOPMENT	PACO RESEARCH CORP	PACO RES
SQUIBB NOVO INC	NOVO NORDISK PHARMS INC	NOVO NORDISK PHARMS
TAKEDA-ABBOTT RESEARCH & DEVELOPMENT	TAP PHARMS INC	TAP PHARMS

DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under sections 505 and 507 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 1989) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

DEFINITIONS

Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product, provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

COUNTS CUMULATIVE BY QUARTER

CATEGORIES COUNTED	DEC 1989	MAR 1990	JUN 1990	SEP 1990
DRUG PRODUCTS LISTED	10123	10095	10083	10047
SINGLE SOURCE	2030 (20.1%)	2039 (20.2%)	2064 (20.5%)	2058 (20.5%)
MULTISOURCE	8093 (79.9%)	8056 (79.8%)	8019 (79.5%)	7989 (79.5%)
THERAPEUTICALLY EQUIVALENT	7222 (71.3%)	7213 (71.5%)	7183 (71.2%)	7147 (71.1%)
NOT THERAPEUTICALLY EQUIVALENT	752 (7.4%)	723 (7.1%)	713 (7.1%)	711 (7.1%)
EXCEPTIONS[1]	119 (1.2%)	120 (1.2%)	123 (1.2%)	131 (1.3%)
NEW MOLECULAR ENTITIES APPROVED	--	3	4	3
NUMBER OF APPLICANTS	400	406	414	416

[1] Amino acid-containing products of varying composition (see Introduction, page 1-8 of the List).

ACETAMINOPHEN; ASPIRIN; CODEINE PHOSPHATE

CAPSULE; ORAL
ACETAMINOPHEN, ASPIRIN, AND CODEINE PHOSPHATE
MIKART — 150MG;180MG;15MG — N81095 001 OCT 26, 1990
150MG;180MG;30MG — N81096 001 OCT 26, 1990
150MG;180MG;60MG — N81097 001 OCT 26, 1990

ACETAMINOPHEN; BUTALBITAL

CAPSULE; ORAL
CONTEN
AB GRAHAM LABS — 650MG;50MG — N89405 001 MAY 15, 1990

TABLET; ORAL
SEDAPAP
MAYRAND — 650MG;50MG — N88944 001 OCT 17, 1985

/SEDAPAP-10/
/MAYRAND/ — /650MG;50MG/ — /N88944/001/ /OCT/17,/1985/

ACETAMINOPHEN; CODEINE PHOSPHATE

TABLET; ORAL
ACETAMINOPHEN AND CODEINE PHOSPHATE #3
/AA/ /SUPERPHARM/ — /300MG;30MG/ — /N89253/001/ /MAY/19,/1986/
∂ SUPERPHARM — 300MG;30MG — N89253 001 MAY 19, 1986

ACETAMINOPHEN AND CODEINE PHOSPHATE #4
/AA/ /SUPERPHARM/ — /300MG;60MG/ — /N89254/001/ /MAY/19,/1986/
∂ SUPERPHARM — 300MG;60MG — N89254 001 MAY 19, 1986

/EMPRACET W/ CODEINE PHOSPHATE #3/
/AA/ /BURROUGHS/WELLCOME/ — /300MG;30MG/ — /N83951/001/
∂ BURROUGHS WELLCOME — 300MG;30MG — N83951 001

/EMPRACET W/ CODEINE PHOSPHATE #4/
/AA/ /BURROUGHS/WELLCOME/ — /300MG;60MG/ — /N83951/002/
∂ BURROUGHS WELLCOME — 300MG;60MG — N83951 002

ACETAMINOPHEN; HYDROCODONE BITARTRATE

TABLET; ORAL
HYDROCODONE BITARTRATE AND ACETAMINOPHEN
/AA/ /PHARM/BASICS/ — /500MG;5MG/ — /N89290/001/ /MAY/29,/1987/
∂ PHARM BASICS — 500MG;5MG — N89290 001 MAY 29, 1987

NORCET
AA ABANA — 500MG;5MG — N88871 001 MAY 15, 1986
/AA/ /HOLLOWAY/ — /500MG;5MG/ — /N88871/001/ /MAY/15,/1986/

ACETIC ACID, GLACIAL

SOLUTION/DROPS; OTIC
ACETIC ACID
>DLT>/AT/ /KV/ — /2%/ — /N85493/001/
>ADD> ∂ KV — 2% — N85493 001

ACETIC ACID, GLACIAL; HYDROCORTISONE

SOLUTION/DROPS; OTIC
>DLT> /ACETIC ACID W/ HYDROCORTISONE/
>DLT>/AT/ /KV/ — /2%;1%/ — /N85492/001/
>ADD> ∂ KV — 2%;1% — N85492 001

ACETYLCYSTEINE

/SOLUTION;/INHALATION/
/ACETYLCYSTEINE/
/AN/ /QUAD/ — /10%/ — /N71740/001/ /AUG/11,/1987/
/AN/ — /20%/ — /N71741/001/ /AUG/11,/1987/

/MUCOSOL-10/
/AN/ /DEY/ — /10%/ — /N70575/001/ /OCT/14,/1986/

/MUCOSOL-20/
/AN/ /DEY/ — /20%/ — /N70576/001/ /OCT/14,/1986/

SOLUTION; INHALATION, ORAL
ACETYLCYSTEINE
AN QUAD — 10% — N71740 001 AUG 11, 1987
AN — 20% — N71741 001 AUG 11, 1987

ACETYLCYSTEINE

SOLUTION; INHALATION, ORAL

	MUCOSOL-10			
AN	DEY LABS	10%	N70575 001	OCT 14, 1986
	MUCOSOL-20			
AN	DEY LABS	20%	N70576 001	OCT 14, 1986

ACETYLDIGITOXIN

/TABLET;/ORAL/

	/ACYLANID/			
/AB/	/SANDOZ/PHARMS/	/0.1MG/	/N09436/001/	
	@ SANDOZ PHARMS	0.1MG	N09436 001	

ALBUTEROL SULFATE

TABLET; ORAL

	ALBUTEROL SULFATE			
AB	LEMMON	EQ 2MG BASE¤	N72938 001	MAR 30, 1990
AB		EQ 4MG BASE¤	N72939 001	MAR 30, 1990
AB	WARNER CHILCOTT	EQ 2MG BASE¤	N72817 001	JAN 09, 1990
AB		EQ 4MG BASE¤	N72818 001	JAN 09, 1990

ALLOPURINOL

TABLET; ORAL

	ALLOPURINOL			
/AB/	/SUPERPHARM/	/100MG/	/N70950/001/	/SEP/04,/1986/
	@ SUPERPHARM	100MG	N70950 001	SEP 04, 1986

ALPRAZOLAM

TABLET; ORAL

	XANAX			
>ADD>	UPJOHN	2MG	N18276 004	NOV 27, 1985
>ADD>				

AMANTADINE HYDROCHLORIDE

SYRUP; ORAL

	AMANTADINE HCL			
AA	BARRE NATL	50MG/5ML¤	N72655 001	OCT 30, 1990
	SYMMETREL			
AA	DUPONT PHARMS	50MG/5ML	N16023 002	
AA		50MG/5ML	N17118 001	

AMILORIDE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

	AMILORIDE HCL AND HYDROCHLOROTHIAZIDE			
/AB/	/BARR/LABS/	/5MG;50MG/	/N71111/001/	/DEC/25,/1990/;/MAY/10,/1988/
AB	BARR LABS	5MG;50MG	N71111 001	MAY 10, 1988

AMINOPHYLLINE

INJECTABLE; INJECTION

	AMINOPHYLLINE			
>DLT>/AP/	/LYPHOMED/	/25MG/ML/	/N84568/001/	
>ADD>	@ LYPHOMED	25MG/ML	N84568 001	

TABLET; ORAL

	AMINOPHYLLINE			
/BD/	@ PAL PAK /VALE/CHEM/	100MG /100MG/	N84533 001 /N84533/001/	

AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

TABLET; ORAL

	PERPHENAZINE AND AMITRIPTYLINE HCL			
/AB/	/CHELSEA/LABS/	/50MG;4MG/	/N71558/001/	/MAR/02,/1987/
BX	CHELSEA LABS	50MG;4MG	N71558 001	MAR 02, 1987

AMMONIUM CHLORIDE

INJECTABLE; INJECTION

/AMMONIUM/CHLORIDE/0.9%/IN/NORMAL/SALINE/

/KENDALL/MCGAW/	/900MG/100ML/	/N06580/001/	
@ KENDALL MCGAW	900MG/100ML	N06580 001	

AMPHETAMINE RESIN COMPLEX; DEXTROAMPHETAMINE RESIN COMPLEX

CAPSULE, EXTENDED RELEASE; ORAL

BIPHETAMINE 12.5			
FISONS	EQ 6.25MG BASE; EQ 6.25MG BASE	N10093 007	
/PENNWALT/	/EQ/6.25MG/BASE;/ /EQ/6.25MG/BASE/	/N10093/007/	
BIPHETAMINE 20			
FISONS	EQ 10MG BASE; EQ 10MG BASE	N10093 003	
/PENNWALT/	/EQ/10MG/BASE;/ /EQ/10MG/BASE/	/N10093/003/	
BIPHETAMINE 7.5			
FISONS	EQ 3.75MG BASE; EQ 3.75MG BASE	N10093 009	
/PENNWALT/	/EQ/3.75MG/BASE;/ /EQ/3.75MG/BASE/	/N10093/009/	

ANTAZOLINE PHOSPHATE; NAPHAZOLINE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

VASOCON-A			
IOLAB PHARMS	0.5%;0.05%¤	N18746 001	APR 30, 1990

ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL

FIORINAL W/CODEINE NO 3			
SANDOZ	325MG;50MG;40MG;30MG¤	N19429 003	OCT 26, 1990

ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE

TABLET; ORAL

/ORPHENADRINE/COMPOUND/

/BX/	/VITARINE/	/385MG;30MG;25MG/	/N71564/001/	/JUN/23,/1988/
	@ VITARINE	385MG;30MG;25MG	N71564 001	JUN 23, 1988

/ORPHENADRINE/COMPOUND/DOUBLE/STRENGTH/

/BX/	/VITARINE/	/770MG;60MG;50MG/	/N71565/001/	/JUN/23,/1988/
	@ VITARINE	770MG;60MG;50MG	N71565 001	JUN 23, 1988

ASPIRIN; MEPROBAMATE

TABLET; ORAL

>DLT>	/MEPRO-ASPIRIN/			
>DLT>/AB/	/VITARINE/	/325MG;200MG/	/N89127/001/	/MAR/02,/1987/
>DLT>				
>ADD>	@ VITARINE	325MG;200MG	N89127 001	MAR 02, 1987
>ADD>				

ASPIRIN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE

TABLET; ORAL

	OXYCODONE AND ASPIRIN			
AA	BARR LABS	325MG;4.5MG;0.38MG	N87794 001	MAY 26, 1982
	/OXYCODONE W/ ASPIRIN/			
/AA/	/BARR/LABS/	/325MG;4.5MG;0.38MG/	/N87794/001/	/MAY/26,/1982/

ATENOLOL

TABLET; ORAL

	TENORMIN			
	ICI PHARM	25MG¤	N18240 004	APR 09, 1990

ATENOLOL; CHLORTHALIDONE

TABLET; ORAL

	ATENOLOL AND CHLORTHALIDONE			
AB	ICI PHARMS	50MG;25MG¤	N72301 001	MAY 31, 1990
AB		100MG;25MG¤	N72302 001	MAY 31, 1990
	TENORETIC 100			
AB	STUART PHARMS	100MG;25MG	N18760 001	JUN 08, 1984
	TENORETIC 50			
AB	STUART PHARMS	50MG;25MG	N18760 002	JUN 08, 1984

ATROPINE SULFATE

AEROSOL, METERED; INHALATION

ATROPINE SULFATE			
DEPT ARMY	EQ 0.36MG BASE/INH¤	N20056 001	SEP 19, 1990

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

TABLET; ORAL

	DIPHENOXYLATE HCL AND ATROPINE SULFATE			
AA	MYLAN	0.025MG;2.5MG	N85762 001	
/AA/	/PARKE/DAVIS/	/0.025MG;2.5MG/	/N87131/001/	
	∂ PARKE DAVIS	0.025MG;2.5MG	N87131 001	
	/DIPHENOXYLATE HCL W/ ATROPINE SULFATE/			
/AA/	/MYLAN/	/0.025MG;2.5MG/	/N85762/001/	

ATROPINE SULFATE; MEPERIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

	ATROPINE AND DEMEROL			
/AP/	/STERLING/	/0.4MG/ML;50MG/ML/	/N87853/001/ /NOV/26,/1982/	
/AP/		/0.4MG/ML;75MG/ML/	/N87847/001/ /NOV/26,/1982/	
/AP/		/0.4MG/ML;100MG/ML/	/N87848/001/ /NOV/26,/1982/	
	STERLING	0.4MG/ML;50MG/ML	N87853 001 NOV 26, 1982	
		0.4MG/ML;75MG/ML	N87847 001 NOV 26, 1982	
		0.4MG/ML;100MG/ML	N87848 001 NOV 26, 1982	
	MEPERIDINE AND ATROPINE SULFATE			
/AP/	/WYETH/AYERST/	/0.4MG/ML;50MG/ML/	/N85121/001/	
/AP/		/0.4MG/ML;75MG/ML/	/N85121/002/	
/AP/		/0.4MG/ML;100MG/ML/	/N85121/003/	
	∂ WYETH AYERST	0.4MG/ML;50MG/ML	N85121 001	
	∂	0.4MG/ML;75MG/ML	N85121 002	
	∂	0.4MG/ML;100MG/ML	N85121 003	

BACLOFEN

TABLET; ORAL

	BACLOFEN			
/BX/	/VITARINE/	/10MG/	/N71901/001/ /APR/13,/1988/	
/BX/		/20MG/	/N71902/001/ /APR/13,/1988/	
	∂ VITARINE	10MG	N71901 001 APR 13, 1988	
	∂	20MG	N71902 001 APR 13, 1988	

BETAMETHASONE DIPROPIONATE

CREAM; TOPICAL

	BETAMETHASONE DIPROPIONATE			
AB	CLAY PARK	EQ 0.05% BASE*	N72536 001 JAN 31, 1990	

LOTION; TOPICAL

	BETAMETHASONE DIPROPIONATE			
AB	CLAY PARK	EQ 0.05% BASE*	N72538 001 JAN 31, 1990	

OINTMENT; TOPICAL

	BETAMETHASONE DIPROPIONATE			
AB	CLAY PARK	EQ 0.05% BASE*	N72526 001 JAN 31, 1990	

BROMPHENIRAMINE MALEATE

INJECTABLE; INJECTION

	BROMPHENIRAMINE MALEATE			
	/STERIS/	/100MG/ML/	/N83820/001/	
	∂ STERIS	100MG/ML	N83820 001	

BROMPHENIRAMINE MALEATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

ELIXIR; ORAL

	BIPHETAP			
/AA/	/PHARM/BASICS/	/4MG/5ML;25MG/5ML/	/N88687/001/ /SEP/26,/1984/	
	PHARM BASICS	4MG/5ML;25MG/5ML	N88687 001 SEP 26, 1984	
	/BROMANATE/			
/AA/	/BARRE/NAT/	/4MG/5ML;25MG/5ML/	/N88688/001/ /FEB/06,/1985/	
	∂ BARRE NAT	4MG/5ML;25MG/5ML	N88688 001 FEB 06, 1985	

BUTABARBITAL SODIUM

TABLET; ORAL

	BUTABARBITAL SODIUM			
/AA/	/REID/ROWELL/	/16.2MG/	/N83606/001/	
/AA/		/32.4MG/	/N83898/001/	
	∂ REID ROWELL	16.2MG	N83606 001	
	∂	32.4MG	N83898 001	
		/48.6MG/	/N83897/001/	
	∂	48.6MG	N83897 001	
		/97.2MG/	/N83896/001/	
	∂	97.2MG	N83896 001	

BUTABARBITAL SODIUM

TABLET; ORAL

	BUTABARBITAL SODIUM			
>DLT >/AA/	/VITARINE/	/15MG/	/N85938/001/	
>ADD >	∂ VITARINE	15MG	N85938 001	

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

	DEXTROSE 5% IN LACTATED RINGER'S IN PLASTIC CONTAINER			
/AP/	/CUTTER/	/20MG/100ML;5GM/100ML;30MG/100ML;/ /600MG/100ML;/ /310MG/100ML/	/N18499/001/	
	∂ CUTTER	20MG/100ML;5GM/100ML;30MG/100ML; 600MG/100ML; 310MG/100ML	N18499 001	
	LACTATED RINGER'S AND DEXTROSE 5% IN PLASTIC CONTAINER			
AP	BAXTER	20MG/100ML;5GM/100ML;30MG/100ML; 600MG/100ML; 310MG/100ML	N16679 001	
	/LACTATED RINGER'S W/ DEXTROSE 5% IN PLASTIC CONTAINER/			
/AP/	/BAXTER/	/20MG/100ML;5GM/100ML;30MG/100ML;/ /600MG/100ML;/ /310MG/100ML/	/N16679/001/	

CALCIUM CHLORIDE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

	TPN ELECTROLYTES IN PLASTIC CONTAINER			
	/ABBOTT/	/16.5MG/ML;25.4MG/ML;74.6MG/ML;/ /121MG/ML;16.1MG/ML/	/N19399/001/ /JUN/16,/1986/	
	∂ ABBOTT	16.5MG/ML;25.4MG/ML;74.6MG/ML; 121MG/ML;16.1MG/ML	N19399 001 JUN 16, 1986	

CALCIUM CHLORIDE; POTASSIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION

	LACTATED RINGER'S IN PLASTIC CONTAINER		
AP	BAXTER	20MG/100ML;30MG/100ML;600MG/100ML; 310MG/100ML	N16682 001

CARTEOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

	OPTIPRESS		
	BURROUGHS WELLCOME	1%*	N19972 001 MAY 23, 1990

CEFADROXIL

CAPSULE; ORAL

	/CEFADROXIL/			
/AB/	/BIOCRAFT/	/EQ 500MG BASE/	/N62695/001/ /FEB/10,/1989/	
/AB/	/PUREPAC/	/EQ 500MG BASE/	/N63017/001/ /JAN/05,/1989/	
/AB/	/ZENITH/	/EQ 500MG BASE/	/N62766/001/ /MAR/03,/1987/	
	∂ BIOCRAFT	EQ 500MG BASE	N62695 001 FEB 10, 1989	
	∂ PUREPAC	EQ 500MG BASE	N63017 001 JAN 05, 1989	
	∂ ZENITH	EQ 500MG BASE	N62766 001 MAR 03, 1987	
	DURICEF			
	/MEAD/JOHNSON/	/EQ/250MG/BASE/	/N50512/002/	
	∂ MEAD JOHNSON	EQ 250MG BASE	N50512 002	

POWDER FOR RECONSTITUTION; ORAL

	/CEFADROXIL/			
/AB/	/BIOCRAFT/	/EQ 125MG BASE/5ML/	/N62698/001/ /MAR/01,/1989/	
/AB/		/EQ 250MG BASE/5ML/	/N62698/002/ /MAR/01,/1989/	
/AB/		/EQ 500MG BASE/5ML/	/N62698/003/ /MAR/01,/1989/	
	∂ BIOCRAFT	EQ 125MG BASE/5ML	N62698 001 MAR 01, 1989	
	∂	EQ 250MG BASE/5ML	N62698 002 MAR 01, 1989	
	∂	EQ 500MG BASE/5ML	N62698 003 MAR 01, 1989	
	DURICEF			
AB	MEAD JOHNSON	EQ 125MG BASE/5ML	N50527 002	
AB		EQ 250MG BASE/5ML	N50527 003	

CEFADROXIL

POWDER FOR RECONSTITUTION; ORAL
ULTRACEF

AB	BRISTOL	EQ 125MG BASE/5ML	N62334 001
AB		EQ 125MG BASE/5ML	N62376 001 MAR 16, 1982
AB		EQ 250MG BASE/5ML	N62334 002
AB		EQ 250MG BASE/5ML	N62376 002 MAR 16, 1982
		/EQ/125MG/BASE/5ML/	/N62334/001/
		/EQ/125MG/BASE/5ML/	/N62376/001/ /MAR/16,/1982/
		/EQ/250MG/BASE/5ML/	/N62334/002/
		/EQ/250MG/BASE/5ML/	/N62376/002/ /MAR/16,/1982/

TABLET; ORAL
/CEFADROXIL/

/AB/	/ZENITH/	/EQ 1GM BASE/	/N62774/001/ /APR/08,/1987/
	ə ZENITH	EQ 1GM BASE	N62774 001 APR 08, 1987

CEFAZOLIN SODIUM

INJECTABLE; INJECTION
CEFAZOLIN SODIUM

AP	LEMMON	EQ 5GM BASE/VIAL*	N63018 001 MAR 05, 1990
AP		EQ 10GM BASE/VIAL*	N63018 002 MAR 05, 1990

CEFOPERAZONE SODIUM

INJECTABLE; INJECTION
CEFOBID

	PFIZER	EQ 1GM BASE/VIAL	N50551 001 NOV 18, 1982
		EQ 2GM BASE/VIAL	N50551 002 NOV 18, 1982
		EQ 10GM BASE/VIAL*	N50551 003 MAR 05, 1990
	/ROERIG/	/EQ/1GM/BASE/VIAL/	/N50551/001/ /NOV/18,/1982/
		/EQ/2GM/BASE/VIAL/	/N50551/002/ /NOV/18,/1982/

CEFOPERAZONE SODIUM

INJECTABLE; INJECTION
CEFOBID IN PLASTIC CONTAINER

	PFIZER	EQ 20MG BASE/ML	N50613 002 JUL 31, 1987
		EQ 40MG BASE/ML	N50613 001 JUL 23, 1986
	/ROERIG/	/EQ/20MG/BASE/ML/	/N50613/002/ /JUL/31,/1987/
		/EQ/40MG/BASE/ML/	/N50613/001/ /JUL/23,/1986/

CEFTAZIDIME

INJECTABLE; INJECTION
CEPTAZ

	GLAXO	500MG/VIAL*	N50646 001 SEP 27, 1990
		1GM/VIAL*	N50646 002 SEP 27, 1990
		2GM/VIAL*	N50646 003 SEP 27, 1990
		10GM/VIAL*	N50646 004 SEP 27, 1990

CEPHALEXIN

CAPSULE; ORAL
CEPHALEXIN MONOHYDRATE

/BX/	/VITARINE/	/EQ/250MG/BASE/	/N62159/001/
/BX/		/EQ/500MG/BASE/	/N62159/002/
	ə VITARINE	EQ 250MG BASE	N62159 001
	ə	EQ 500MG BASE	N62159 002

POWDER FOR RECONSTITUTION; ORAL
CEPHALEXIN

/BX/	/VITARINE/	/EQ/125MG/BASE/5ML/	/N62779/001/ /DEC/22,/1987/
/BX/		/EQ/250MG/BASE/5ML/	/N62781/001/ /DEC/22,/1987/
	ə VITARINE	EQ 125MG BASE/5ML	N62779 001 DEC 22, 1987
	ə	EQ 250MG BASE/5ML	N62781 001 DEC 22, 1987

CEPHALEXIN

TABLET; ORAL
CEPHALEXIN

/BX/	/VITARINE/	/EQ/250MG/BASE/	/N62863/001/ /AUG/11,/1988/
/BX/		/EQ/500MG/BASE/	/N62863/002/ /AUG/11,/1988/
/BX/		/EQ/1GM/BASE/	/N62863/003/ /AUG/11,/1988/
	ə VITARINE	EQ 250MG BASE	N62863 001 AUG 11, 1988
	ə	EQ 500MG BASE	N62863 002 AUG 11, 1988
	ə	EQ 1GM BASE	N62863 003 AUG 11, 1988

CEPHAPIRIN SODIUM

INJECTABLE; INJECTION
CEPHAPIRIN SODIUM

/AP/	/LYPHOMED/	/EQ 20GM BASE/VIAL/	/N62723/005/ /NOV/17,/1986/
	ə LYPHOMED	EQ 20GM BASE/VIAL	N62723 005 NOV 17, 1986

CEPHRADINE

CAPSULE; ORAL
CEPHRADINE

/BX/	/VITARINE/	/250MG/	/N62813/001/ /FEB/25,/1988/	>DLT> >DLT> >DLT>
/BX/		/500MG/	/N62813/002/ /FEB/25,/1988/	>ADD> >ADD> >ADD>
	ə VITARINE	250MG	N62813 001 FEB 25, 1988	
	ə	500MG	N62813 002 FEB 25, 1988	

CHLORDIAZEPOXIDE; ESTROGENS, CONJUGATED

/TABLET;/ORAL/			
/MENRIUM/10-4/ /ROCHE/		/10MG;0.4MG/	/N14740/006/
/MENRIUM/5-2/ /ROCHE/		/5MG;0.2MG/	/N14740/002/
/MENRIUM/5-4/ /ROCHE/		/5MG;0.4MG/	/N14740/004/

CHLORDIAZEPOXIDE; ESTROGENS, ESTERIFIED

TABLET; ORAL

	MENRIUM 10-4 ROCHE	10MG;0.4MG	N14740 006
	MENRIUM 5-2 ROCHE	5MG;0.2MG	N14740 002
	MENRIUM 5-4 ROCHE	5MG;0.4MG	N14740 004

CHLORPHENIRAMINE MALEATE

TABLET; ORAL
CHLORPHENIRAMINE MALEATE

/AA/	/PUREPAC/	/4MG/	/N86306/001/
	ə PUREPAC	4MG	N86306 001
/AA/	/ROXANE/	/4MG/	/N80626/001/
	ə ROXANE	4MG	N80626 001

CHLORZOXAZONE

TABLET; ORAL
CHLORZOXAZONE

AA	MUTUAL PHARM	500MG*	N89970 001 SEP 27, 1990

CHROMIC PHOSPHATE, P-32

	/INJECTABLE;/INJECTION/		
	/PHOSPHOCOL/P/32/		
	/MALLINCKRODT/	/5MCI/ML/	/N17084/001/
	INJECTABLE; INJECTION PHOSPHOCOL P32		
	MALLINCKRODT	5MCI/ML	N17084 001

CIMETIDINE HYDROCHLORIDE

INJECTABLE; INJECTION
TAGAMET HCL IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

	SKF	EQ 6MG BASE/ML	N19434 001 OCT 31, 1985
	/TAGAMET/IN/SODIUM/CHLORIDE/0.9%/IN/PLASTIC/CONTAINER/		
	/SKF/	/EQ/6MG/BASE/ML/	/N19434/001/ /OCT/31,/1985/

CITRIC ACID; GLUCONOLACTONE; MAGNESIUM CARBONATE

SOLUTION; IRRIGATION
RENACIDIN
UNITED GUARDIAN — 6.602GM/100ML;0.198GM/100ML; 3.177GM/100ML — N19481 001 OCT 02, 1990

CLINDAMYCIN HYDROCHLORIDE

CAPSULE; ORAL
CLINDAMYCIN HCL

/BX/	/VITARINE/	/EQ/75MG/BASE/	/N62910/001/ /JUL/05,/1988/
/BX/		/EQ/150MG/BASE/	/N62910/002/ /JUL/05,/1988/
ə	VITARINE	EQ 75MG BASE	N62910 001 JUL 05, 1988
ə		EQ 150MG BASE	N62910 002 JUL 05, 1988

CLINDAMYCIN PHOSPHATE

INJECTABLE; INJECTION
CLINDAMYCIN PHOSPHATE

AP	LEMMON	EQ 150MG BASE/ML	N63079 001 MAR 05, 1990

CLOBETASOL PROPIONATE

SOLUTION; TOPICAL
TEMOVATE
GLAXO — 0.05% — N19966 001 FEB 22, 1990

CLOCORTOLONE PIVALATE

CREAM; TOPICAL
CLODERM

HERMAL	0.1%	N17765 001
/JOHNSON/RW/	/0.1%/	/N17765/001/

CLONIDINE HYDROCHLORIDE

TABLET; ORAL
CLONIDINE HCL

/AB/	/INTERPHARM/	/0.1MG/	/N71252/001/ /OCT/01,/1986/
/AB/		/0.2MG/	/N71253/001/ /OCT/01,/1986/
/AB/		/0.3MG/	/N71254/001/ /OCT/01,/1986/
BX	INTERPHARM	0.1MG	N71252 001 OCT 01, 1986
BX		0.2MG	N71253 001 OCT 01, 1986
BX		0.3MG	N71254 001 OCT 01, 1986

CLORAZEPATE DIPOTASSIUM

CAPSULE; ORAL
CLORAZEPATE DIPOTASSIUM

/AB/	/WARNER/CHILCOTT/	/3.75MG/	/N71774/001/ /MAR/01,/1988/
/AB/		/7.5MG/	/N71775/001/ /MAR/01,/1988/
/AB/		/15MG/	/N71776/001/ /MAR/01,/1988/
ə	WARNER CHILCOTT	3.75MG	N71774 001 MAR 01, 1988
ə		7.5MG	N71775 001 MAR 01, 1988
ə		15MG	N71776 001 MAR 01, 1988

TABLET; ORAL
CLORAZEPATE DIPOTASSIUM

AB	CORD	3.75MG	N72512 001 MAY 11, 1990
AB		7.5MG	N72513 001 MAY 11, 1990
AB		15MG	N72514 001 MAY 11, 1990

CLOTRIMAZOLE

CREAM; VAGINAL

>DLT>	/GYNE-LOTRIMIN/			
>DLT>/AT/	/SCHERING/	/1%/		/N18052/001/
	MYCELEX-G			
>DLT>/AT/	/MILES/	/1%/		/N18230/001/
>ADD>	MILES	1%		N18230 001

RX DRUG PRODUCT LIST / CUMULATIVE SUPPLEMENT NUMBER 11 / JAN'90 - NOV'90

CLOTRIMAZOLE

TABLET; VAGINAL

>DLT>	/GYNE-LOTRIMIN/			
>DLT>/AT/	/SCHERING/	/100MG/	/N17717/001/	
	MYCELEX-G			
>DLT>/AT/	/MILES/PHARM/	/100MG/	/N18182/001/	
>ADD>	MILES PHARM	100MG	N18182 001	

CODEINE PHOSPHATE; PSEUDOEPHEDRINE HYDROCHLORIDE; TRIPROLIDINE HYDROCHLORIDE

SYRUP; ORAL
/PSEUDODINE-C/

/AA/	/PBI/	/10MG/5ML;30MG/5ML;/ /1.25MG/5ML/	/N88833/001/ /NOV/16,/1984/	

TRIPROLIDINE HCL, PSEUDOEPHEDRINE HCL AND CODEINE PHOSPHATE

AA	PBI	10MG/5ML;30MG/5ML; 1.25MG/5ML	N88833 001 NOV 16, 1984

COLFOSCERIL PALMITATE

POWDER FOR RECONSTITUTION; INTRATRACHEAL
EXOSURF NEONATAL
BURROUGHS WELLC — 108MG/VIAL — N20044 001 AUG 02, 1990

CYANOCOBALAMIN; TANNIC ACID; ZINC ACETATE

/INJECTABLE;/INJECTION/ /DEPINAR/			
/ARMOUR/PHARM/	/0.5MG/ML;2.3MG/ML;/ /1MG/ML/	/N11208/001/	
ə ARMOUR PHARM	0.5MG/ML;2.3MG/ML; 1MG/ML	N11208 001	

CYCLOSPORINE

CAPSULE; ORAL
SANDIMMUNE
SANDOZ PHARMS — 25MG — N50625 001 MAR 02, 1990
100MG — N50625 002 MAR 02, 1990

CYPROHEPTADINE HYDROCHLORIDE

TABLET; ORAL
CYPROHEPTADINE HCL

>DLT>/AA/	/KV/PHARM/	/4MG/	/N86737/001/	
>ADD>	ə KV PHARM	4MG	N86737 001	

CYTARABINE

INJECTABLE; INJECTION
CYTARABINE
BULL LABS — 20MG/ML — N71868 001 JUN 04, 1990
20MG/ML — N72168 001 AUG 31, 1990

DESIPRAMINE HYDROCHLORIDE

TABLET; ORAL
DESIPRAMINE HCL

/BX/	/VITARINE/	/10MG/	/N72167/001/ /FEB/03,/1988/
/BX/		/25MG/	/N71601/001/ /JUN/05,/1987/
/BX/		/50MG/	/N71588/001/ /JUN/05,/1987/
/BX/		/75MG/	/N71602/001/ /OCT/05,/1987/
/BX/		/100MG/	/N71766/001/ /OCT/05,/1987/
/BX/		/150MG/	/N72254/001/ /FEB/03,/1988/
ə	VITARINE	10MG	N72167 001 FEB 03, 1988
ə		25MG	N71601 001 JUN 05, 1987
ə		50MG	N71588 001 JUN 05, 1987
ə		75MG	N71602 001 OCT 05, 1987
ə		100MG	N71766 001 OCT 05, 1987
ə		150MG	N72254 001 FEB 03, 1988

DESOXIMETASONE

CREAM; TOPICAL

>ADD>		**DESOXIMETASONE**		
>ADD>	AB	TARO	0.05%◊	N73210 001 NOV 30, 1990
>ADD>				
>ADD>	AB		0.25%◊	N73193 001 NOV 30, 1990
>ADD>				
		TOPICORT		
>ADD>	AB	HOECHST ROUSSEL	0.25%	N17856 001
		TOPICORT LP		
>ADD>	AB	HOECHST ROUSSEL	0.05%	N18309 001

DEXAMETHASONE

TABLET; ORAL

		DEXAMETHASONE		
		∂ BARR	0.5MG	N84766 001

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION

		DEXAMETHASONE SODIUM PHOSPHATE		
/AP/	/INTL/MEDICATION/	/EQ 20MG PHOSPHATE/ML/		/N88522/001/ /FEB/17,/1984/
	∂ INTL MEDICATION	EQ 20MG PHOSPHATE/ML		N88522 001 FEB 17, 1984
AP	KENDALL MCGAW	EQ 4MG PHOSPHATE/ML◊		N81125 001 AUG 31, 1990
AP		EQ 10MG PHOSPHATE/ML◊		N81126 001 AUG 31, 1990

OINTMENT; OPHTHALMIC

		MAXIDEX		
AT	ALCON	EQ 0.05% PHOSPHATE		N83342 001

/OINTMENT;/OPHTHALMIC;/OTIC/

		/MAXIDEX/		
/AT/	/ALCON/	/EQ 0.05% PHOSPHATE/		/N83342/001/

/SOLUTION/DROPS;/OPHTHALMIC/

		/DEXAMETHASONE SODIUM PHOSPHATE/		
/AT/	/STERIS/	/EQ 0.1% PHOSPHATE/		/N88771/001/ /JAN/16,/1985/

SOLUTION/DROPS; OPHTHALMIC, OTIC

		DEXAMETHASONE SODIUM PHOSPHATE		
AT	STERIS	EQ 0.1% PHOSPHATE		N88771 001 JAN 16, 1985

DEXTROSE; SODIUM CHLORIDE

INJECTABLE; INJECTION

		DEXTROSE 3.3% AND SODIUM CHLORIDE 0.3% IN PLASTIC CONTAINER		
		KENDALL MCGAW	3.3GM/100ML; 300MG/100ML◊	N19631 016 JAN 19, 1990

DEZOCINE

INJECTABLE; INJECTION

		DALGAN		
		ASTRA	5MG/ML	N19082 001 DEC 29, 1989
			10MG/ML	N19082 002 DEC 29, 1989
			15MG/ML	N19082 003 DEC 29, 1989
	/WYETH/AYERST/		/5MG/ML/	/N19082/001/ /DEC/29,/1989/
			/10MG/ML/	/N19082/002/ /DEC/29,/1989/
			/15MG/ML/	/N19082/003/ /DEC/29,/1989/

DIATRIZOATE MEGLUMINE; DIATRIZOATE SODIUM

INJECTABLE; INJECTION

		/HYPAQUE-M/		
		/STERLING/	/50%;25%/	/N10220/003/
		/∂/	/60%;30%/	/N10220/002/
		HYPAQUE-M,75%		
		STERLING	50%;25%	N10220 003
		HYPAQUE-M,90%		
		STERLING	60%;30%	N10220 002

DIAZEPAM

TABLET; ORAL

		DIAZEPAM		
/BX/	/SUPERPHARM/		/10MG/	/N70644/001/ /DEC/11,/1985/
	∂ SUPERPHARM		10MG	N70644 001 DEC 11, 1985

DICLOXACILLIN SODIUM

POWDER FOR RECONSTITUTION; ORAL

		DYNAPEN		
/AB/	/BRISTOL/	/EQ 62.5MG BASE/5ML/		/N50337/002/
	∂ BRISTOL	EQ 62.5MG BASE/5ML		N50337 002

DIETHYLPROPION HYDROCHLORIDE

TABLET; ORAL

		TENUATE		
/AA/	/MERRELL/DOW/		/25MG/	/N17668/001/
	∂ MERRELL DOW		25MG	N17668 001

TABLET, EXTENDED RELEASE; ORAL

		/TENUATE/		
/BC/	/MERRELL/DOW/		/75MG/	/N17669/001/
	∂ MERRELL DOW		75MG	N17669 001

DIGOXIN

INJECTABLE; INJECTION

		DIGOXIN		
>DLT>/AA/	/LYPHOMED/		/0.25MG/ML/	/N83217/001/
>ADD>	∂ LYPHOMED		0.25MG/ML	N83217 001

DIHYDROERGOTAMINE MESYLATE; HEPARIN SODIUM; LIDOCAINE HYDROCHLORIDE

/INJECTABLE;/INJECTION/

		/EMBOLEX/		
		/SANDOZ/	/0.5MG/0.7ML;5,000/UNITS/0.7ML;/ /7.46MG/0.7ML/	/N18885/002/ /NOV/30,/1984/
	∂ SANDOZ		0.5MG/0.7ML;5,000 UNITS/0.7ML; 7.46MG/0.7ML	N18885 002 NOV 30, 1984

DIMENHYDRINATE

TABLET; ORAL

		DIMENHYDRINATE		
/AA/	/ANABOLIC/		/50MG/	/N85985/001/
	∂ ANABOLIC		50MG	N85985 001

DINOPROST TROMETHAMINE

/INJECTABLE;/INJECTION/

		/PROSTIN/F2/ALPHA/		
		/UPJOHN/	/EQ/5MG/BASE/ML/	/N17434/001/
	∂ UPJOHN		EQ 5MG BASE/ML	N17434 001

DIPHENHYDRAMINE HYDROCHLORIDE

CAPSULE; ORAL

		DIPHENHYDRAMINE HCL		
	/AA/	/ANABOLIC/	/25MG/	/N83634/001/
	∂ ANABOLIC		25MG	N83634 001
>DLT>/AA/	/HEATHER/		/25MG/	/N84524/001/
/AA/			/50MG/	/N83953/001/
>ADD>	∂ HEATHER		25MG	N84524 001
	∂		50MG	N83953 001

DIPYRIDAMOLE

TABLET; ORAL

		DIPYRIDAMOLE		
>ADD>	AB	BARR	25MG◊	N87184 001 OCT 03, 1990
>ADD>				
>ADD>	AB		50MG◊	N87716 001 OCT 03, 1990
>ADD>				
>ADD>	AB		75MG◊	N87717 001 OCT 03, 1990
>ADD>				
	AB	PUREPAC	25MG◊	N89425 001 JUL 12, 1990
	AB		50MG◊	N89426 001 JUL 12, 1990
	AB		75MG◊	N89427 001 JUL 12, 1990
		PERSANTINE		
	AB	BOEHRINGER INGELHEIM	25MG	N12836 003 DEC 22, 1986
	AB		50MG	N12836 004 FEB 06, 1987
	AB		75MG	N12836 005 FEB 06, 1987

DISOPYRAMIDE PHOSPHATE

CAPSULE; ORAL

	DISOPYRAMIDE PHOSPHATE			
/AB/	/CHELSEA/	/EQ 100MG BASE/	/N71020/001/	/DEC/01,/1986/
/AB/		/EQ 150MG BASE/	/N71021/001/	/DEC/01,/1986/
BX	CHELSEA	EQ 100MG BASE	N71020 001	DEC 01, 1986
BX		EQ 150MG BASE	N71021 001	DEC 01, 1986
/AB/	/SUPERPHARM/	/EQ 150MG BASE/	/N70941/001/	/FEB/09,/1987/
	∂ SUPERPHARM	EQ 150MG BASE	N70941 001	FEB 09, 1987

DIVALPROEX SODIUM

TABLET, DELAYED RELEASE; ORAL

DEPAKOTE CP			
ABBOTT	EQ 250MG BASE¤	N19794 001	JUL 11, 1990
	EQ 500MG BASE¤	N19794 002	JUL 11, 1990

> ADD > DOXAZOSIN MESYLATE

> ADD > TABLET; ORAL

> ADD >	CARDURA		
> ADD >	PFIZER	EQ 1MG BASE¤	N19668 001 NOV 02, 1990
> ADD >		EQ 2MG BASE¤	N19668 002 NOV 02, 1990
> ADD >		EQ 4MG BASE¤	N19668 003 NOV 02, 1990
> ADD >		EQ 8MG BASE¤	N19668 004 NOV 02, 1990

DOXEPIN HYDROCHLORIDE

CAPSULE; ORAL

	ADAPIN		
AB	FISONS	EQ 10MG BASE	N16987 001
AB		EQ 25MG BASE	N16987 002
AB		EQ 50MG BASE	N16987 003
AB		EQ 75MG BASE	N16987 006
AB		EQ 100MG BASE	N16987 004
AB		EQ 150MG BASE	N16987 007 APR 13, 1987

DOXEPIN HYDROCHLORIDE

CAPSULE; ORAL

	ADAPIN		
/AB/	/PENNWALT/	/EQ 10MG BASE/	/N16987/001/
/AB/		/EQ 25MG BASE/	/N16987/002/
/AB/		/EQ 50MG BASE/	/N16987/003/
/AB/		/EQ 75MG BASE/	/N16987/006/
/AB/		/EQ 100MG BASE/	/N16987/004/
/AB/		/EQ 150MG BASE/	/N16987/007/ /APR/13,/1987/

DOXORUBICIN HYDROCHLORIDE

INJECTABLE; INTRAVENOUS

	DOXORUBICIN HCL			
AP	PHARMACHEMIE	10MG/VIAL¤	N63097 001	MAY 21, 1990
AP		20MG/VIAL¤	N63097 002	MAY 21, 1990
AP		50MG/VIAL¤	N63097 003	MAY 21, 1990

DOXYCYCLINE HYCLATE

CAPSULE; ORAL

	DOXYCYCLINE HYCLATE			
/BX/	/VITARINE/	/EQ/50MG/BASE/	/N62780/001/	/APR/12,/1988/
/BX/		/EQ/100MG/BASE/	/N62227/001/	
	∂ VITARINE	EQ 50MG BASE	N62780 001	APR 12, 1988
	∂	EQ 100MG BASE	N62227 001	

INJECTABLE; INJECTION

	VIBRAMYCIN		
AP	PFIZER	EQ 100MG BASE/VIAL	N50442 002
AP		EQ 200MG BASE/VIAL	N50442 001
/∂/		/EQ/100MG/BASE/VIAL/	/N50442/002/
/∂/		/EQ/200MG/BASE/VIAL/	/N50442/001/

DYDROGESTERONE

TABLET; ORAL

	GYNOREST		
/∂/	/KALI/DUPHAR/	/5MG/	/N17388/001/
/∂/		/10MG/	/N17388/002/
∂	REID ROWELL	5MG	N17388 001
∂		10MG	N17388 002

RX DRUG PRODUCT LIST / CUMULATIVE SUPPLEMENT NUMBER 11 / JAN'90 - NOV'90 13

> ADD > EFLORNITHINE HYDROCHLORIDE

> ADD > INJECTABLE; INJECTION

> ADD >	ORNIDYL			
> ADD >	MERRELL DOW	200MG/ML¤	N19879 002	NOV 28, 1990

EPINEPHRINE; LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

	LIDOCAINE HCL AND EPINEPHRINE			
AP	ELKINS SINN	0.01MG/ML;1%	N80406 001	
AP		0.01MG/ML;2%	N80406 002	
	/LIDOCAINE HCL W/ EPINEPHRINE/			
/AP/	/ELKINS/SINN/	/0.01MG/ML;1%/	/N80406/001/	
/AP/		/0.01MG/ML;2%/	/N80406/002/	

ERGOLOID MESYLATES

TABLET; ORAL

	/GERIMAL/			
/AB/	/CHELSEA/	/1MG/	/N88207/001/	/MAR/22,/1984/
	∂ CHELSEA	1MG	N88207 001	MAR 22, 1984

TABLET; SUBLINGUAL

	ERGOLOID MESYLATES			
/AB/	/SUPERPHARM/	/0.5MG/	/N89233/001/	/SEP/23,/1986/
/AB/		/1MG/	/N89234/001/	/SEP/23,/1986/
	∂ SUPERPHARM	0.5MG	N89233 001	SEP 23, 1986
	∂	1MG	N89234 001	SEP 23, 1986

ERYTHROMYCIN

CAPSULE, DELAYED REL PELLETS; ORAL

	ERYC		
AB	FAULDING	250MG	N50536 001

ERYTHROMYCIN

SOLUTION; TOPICAL

	ERYTHROMYCIN			
/AT/	/BARRE/NAT/	/2%/	/N62327/001/	/APR/19,/1982/
/AT/		/2%/	/N62342/001/	/FEB/25,/1982/
	∂ BARRE NAT	2%	N62327 001	APR 19, 1982
	∂	2%	N62342 001	FEB 25, 1982

TABLET, DELAYED RELEASE; ORAL

	E-BASE		
AB	BARR	333MG¤	N63028 001 MAY 15, 1990
AB		333MG¤	N63086 001 MAY 15, 1990
	E-MYCIN		
AB	BOOTS	250MG	N60272 001
AB		333MG	N60272 002
/AB/	/UPJOHN/	/250MG/	/N60272/001/
/AB/		/333MG/	/N60272/002/

ERYTHROMYCIN ESTOLATE

SUSPENSION; ORAL

	ERYTHROMYCIN ESTOLATE			
AB	BARR	EQ 125MG BASE/5ML¤	N62169 001	OCT 17, 1990
AB		EQ 250MG BASE/5ML¤	N62169 002	OCT 17, 1990

ERYTHROMYCIN ETHYLSUCCINATE; SULFISOXAZOLE ACETYL

GRANULE; ORAL

	ERYTHROMYCIN ETHYLSUCCINATE AND SULFISOXAZOLE ACETYL			
AB	BARR	EQ 200MG BASE/5ML; EQ 600MG BASE/5ML	N62759 001	MAY 20, 1988

ERYTHROMYCIN STEARATE

TABLET; ORAL

	ERYTHROMYCIN STEARATE			
AB	BARR	EQ 500MG BASE¤	N63179 001	MAY 15, 1990

ESTRADIOL VALERATE; TESTOSTERONE ENANTHATE

INJECTABLE; INJECTION

DITATE-DS

/AA/	/SAVAGE/	/8MG/ML;180MG/ML/	/N86423/001/	
	SAVAGE	8MG/ML;180MG/ML	N86423 001	

TESTOSTERONE ENANTHATE AND ESTRADIOL VALERATE

AO	STERIS	4MG/ML;90MG/ML	N85865 001	
	∂	8MG/ML;180MG/ML	N85860 001	

/TESTOSTERONE ENANTHATE-ESTRADIOL VALERATE/

/AA/	/STERIS/	/4MG/ML;90MG/ML/	/N85865/001/	
/AO/		/8MG/ML;180MG/ML/	/N85860/001/	

ESTROGENS, CONJUGATED

TABLET; ORAL

CONJUGATED ESTROGENS

/BP/	/CHELSEA/	/0.625MG/	/N85800/001/	
	∂ CHELSEA	0.625MG	N85800 001	

ESTROGENS, ESTERIFIED

TABLET; ORAL

FEMOGEN

/BS/	/PRIVATE/FORM/	/1.25MG/	/N85008/001/	
	∂ PRIVATE FORM	1.25MG	N85008 001	

ETHANOLAMINE OLEATE

INJECTABLE; INJECTION

ETHAMOLIN

	BLOCK DRUG	50MG/ML	N19357 001	
			DEC 22, 1988	
	/GLAXO/	/50MG/ML/	/N19357/001/	
			/DEC/22,/1988/	

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-21

NORETHIN 1/35E-21

AB	SCHIAPPARELLI SEARLE	0.035MG;1MG	N71480 001	
			APR 12, 1988	
/AB/	/SEARLE/	/0.035MG;1MG/	/N71480/001/	
			/APR/12,/1988/	

TABLET; ORAL-28

NORETHIN 1/35E-28

AB	SCHIAPPARELLI SEARLE	0.035MG;1MG	N71481 001	
			APR 12, 1988	

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET; ORAL-28

NORETHIN 1/35E-28

/AB/	/SEARLE/	/0.035MG;1MG/	/N71481/001/	
			/APR/12,/1988/	

ETHYLESTRENOL

/ELIXIR;/ORAL/

/MAXIBOLIN/

	/ORGANON/	/2MG/5ML/	/N14006/002/	
	∂ ORGANON	2MG/5ML	N14006 002	

FENTANYL

FILM, EXTENDED RELEASE; TRANSDERMAL

DURAGESIC

ALZA	0.6MG/24HR✠	N19813 004	
		AUG 07, 1990	
	1.2MG/24HR✠	N19813 003	
		AUG 07, 1990	
	1.8MG/24HR✠	N19813 002	
		AUG 07, 1990	
	2.4MG/24HR✠	N19813 001	
		AUG 07, 1990	

FENTANYL CITRATE

INJECTABLE; INJECTION

FENTANYL CITRATE

AP	ABBOTT	EQ 0.05MG BASE/ML✠	N70636 001
			APR 30, 1990
AP		EQ 0.05MG BASE/ML✠	N70637 001
			APR 30, 1990

FLUCONAZOLE

INJECTABLE; INJECTION

DIFLUCAN

PFIZER	2MG/ML✠	N19950 001	
		JAN 29, 1990	

FLUCONAZOLE

TABLET; ORAL

DIFLUCAN

PFIZER	50MG✠	N19949 001	
		JAN 29, 1990	
	100MG✠	N19949 002	
		JAN 29, 1990	
	200MG✠	N19949 003	
		JAN 29, 1990	

FLUNISOLIDE

/SPRAY;/INHALATION/NASAL/

/NASALIDE/			
/SYNTEX/	/0.025MG/INH/	/N18148/001/	

SPRAY, METERED; NASAL

NASALIDE

SYNTEX	0.025MG/INH	N18148 001	

FLUOCINOLONE ACETONIDE

CREAM; TOPICAL

FLUOCINOLONE ACETONIDE

/AT/	/PHARM/BASICS/	/0.01%/	/N88757/001/	
			/FEB/11,/1985/	
/AT/		/0.025%/	/N88756/001/	
			/MAR/28,/1985/	
	∂ PHARM BASICS	0.01%	N88757 001	
			FEB 11, 1985	
	∂	0.025%	N88756 001	
			MAR 28, 1985	

OINTMENT; TOPICAL

FLUOCINOLONE ACETONIDE

/AT/	/PHARM/BASICS/	/0.025%/	/N88742/001/	
			/FEB/08,/1985/	
	∂ PHARM BASICS	0.025%	N88742 001	
			FEB 08, 1985	

SHAMPOO; TOPICAL

FS SHAMPOO

HILL DERMAC	0.01%✠	N20001 001	
		AUG 27, 1990	

FLUOCINONIDE

SOLUTION; TOPICAL

FLUOCINONIDE

AT	COPLEY	0.05%✠	N72522 001
			SEP 28, 1990

FOLIC ACID

TABLET; ORAL

FOLIC ACID

/AA/	/ANABOLIC/	/1MG/	/N84915/001/	
	∂ ANABOLIC	1MG	N84915 001	

FUROSEMIDE

INJECTABLE; INJECTION

FUROSEMIDE

AP	LEDERLE	10MG/ML✠	N71439 001	
			SEP 14, 1990	
>DLT >/AP/	/LYPHOMED/	/10MG/ML/	/N19036/001/	
>DLT >			/AUG/13,/1984/	
>ADD >	∂ LYPHOMED	10MG/ML	N19036 001	
>ADD >			AUG 13, 1984	

GONADOTROPIN, CHORIONIC

INJECTABLE; INJECTION

CHORIONIC GONADOTROPIN

/AP/	/LYPHOMED/	/15,000 UNITS/VIAL/	/N17067/004/	
	∂ LYPHOMED	15,000 UNITS/VIAL	N17067 004	
/AP/	/STERIS/	/15,000 UNITS/VIAL/	/N17016/010/	
			/FEB/15,/1985/	
	STERIS	2,000 UNITS/VIAL✠	N17016 011	
			FEB 16, 1990	
		15,000 UNITS/VIAL	N17016 010	
			FEB 15, 1985	

HALCINONIDE

CREAM; TOPICAL

HALOG

/AT/	/SQUIBB/	/0.1%/	/N17556/001/	
		/0.025%/	/N17818/001/	
	WESTWOOD	0.025%	N17818 001	
		0.1%	N17556 001	

HALOG-E

/AT/	/SQUIBB/	/0.1%/	/N18234/001/	
	WESTWOOD	0.1%	N18234 001	

HALCINONIDE

OINTMENT; TOPICAL

	HALOG		
/$Q/	/EQUIBB/	/0.1%/	/N17824/001/
	WESTWOOD	0.1%	N17824 001

SOLUTION; TOPICAL

	HALOG		
/$Q/	/EQUIBB/	/0.1%/	/N17823/001/
	WESTWOOD	0.1%	N17823 001

HEPARIN SODIUM

INJECTABLE; INJECTION

	HEPARIN LOCK FLUSH		
/AP/	/LYPHOMED/	/100 UNITS/ML/	/N17651/010/
	ə LYPHOMED	100 UNITS/ML	N17651 010
/AP/	/SOLOPAK/	/10 UNITS/ML/	/N87958/001/ /APR/20,/1983/
	ə SOLOPAK	10 UNITS/ML	N87958 001 APR 20, 1983
	HEPARIN SODIUM		
/AP/	/CHAMBERLIN/	/1,000 UNITS/ML/	/N17130/001/
/AP/		/5,000 UNITS/ML/	/N17130/002/
/AP/		/10,000 UNITS/ML/	/N17130/003/
/AP/		/20,000 UNITS/ML/	/N17130/004/
	ə CHAMBERLIN	1,000 UNITS/ML	N17130 001
	ə	5,000 UNITS/ML	N17130 002
	ə	10,000 UNITS/ML	N17130 003
	ə	20,000 UNITS/ML	N17130 004
/AP/	/LYPHOMED/	/1,000 UNITS/ML/	/N17033/001/
/AP/		/1,000 UNITS/ML/	/N17651/005/
/AP/		/10,000 UNITS/ML/	/N17651/003/
/AP/		/20,000 UNITS/ML/	/N17651/008/
	ə LYPHOMED	1,000 UNITS/ML	N17033 001
	ə	1,000 UNITS/ML	N17651 005
	ə	10,000 UNITS/ML	N17651 003
	ə	20,000 UNITS/ML	N17651 008
	/WYETH/AYERST/	/15,000/UNITS/ML/	/N17007/005/
	ə WYETH AYERST	15,000 UNITS/ML	N17007 005

HOMATROPINE METHYLBROMIDE

/TABLET;/CHEWABLE;/ORAL/

	/EQUIPIN/		
	/MISSION/PHARMA/	/3MG/	/N86310/001/
	ə MISSION PHARMA	3MG	N86310 001

HYDRALAZINE HYDROCHLORIDE

TABLET; ORAL

	HYDRALAZINE HCL			
/AA/	/SUPERPHARM/	/10MG/		/N88787/001/ /AUG/28,/1984/
/AA/		/25MG/		/N88788/001/ /AUG/28,/1984/
/AA/		/50MG/		/N88789/001/ /AUG/28,/1984/
	ə SUPERPHARM	10MG		N88787 001 AUG 28, 1984
	ə	25MG		N88788 001 AUG 28, 1984
	ə	50MG		N88789 001 AUG 28, 1984

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

CAPSULE; ORAL

	HYDRALAZINE HCL AND HYDROCHLOROTHIAZIDE			
/AA/	/SUPERPHARM/	/25MG;25MG/		/N89200/001/ /FEB/09,/1987/
	ə SUPERPHARM	25MG;25MG		N89200 001 FEB 09, 1987

TABLET; ORAL

	HYDRALAZINE AND HYDROCHLORTHIAZIDE			
/BP/	/CHELSEA/	/25MG;15MG/		/N85827/001/
	ə CHELSEA	25MG;15MG		N85827 001

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE; RESERPINE

TABLET; ORAL

	UNIPRES			
/BP/	/REID/ROWELL/	/25MG;15MG;0.1MG/		/N85893/001/
	ə REID ROWELL	25MG;15MG;0.1MG		N85893 001

HYDROCHLOROTHIAZIDE

TABLET; ORAL

	HYDROCHLOROTHIAZIDE			
/AB/	/REID/ROWELL/	/25MG/		/N85323/001/
	ə REID ROWELL	25MG		N85323 001

HYDROCHLOROTHIAZIDE; LISINOPRIL

TABLET; ORAL

	PRINZIDE 12.5			
AB	MSD	12.5MG;20MG		N19778 001 FEB 16, 1989
	ZESTORETIC 20/12.5			
AB	IMPERIAL CHEM	12.5MG;20MG		N19888 001 SEP 20, 1990

HYDROCHLOROTHIAZIDE; TRIAMTERENE

CAPSULE; ORAL

	DYAZIDE			
/AB/	/SKF/	/25MG;50MG/		/N16042/002/
	SKF	25MG;50MG		N16042 002
	/TRIAMTERENE/AND/HYDROCHLOROTHIAZIDE/			
/BX/	/BOLAR/	/25MG;50MG/		/N71845/001/ /AUG/21,/1987/

TABLET; ORAL

	TRIAMTERENE AND HYDROCHLOROTHIAZIDE			
/BX/	/VITARINE/	/50MG;75MG/		/N71360/001/ /DEC/08,/1987/
	ə VITARINE	50MG;75MG		N71360 001 DEC 08, 1987

HYDROCODONE BITARTRATE; PHENYLPROPANOLAMINE HYDROCHLORIDE

SYRUP; ORAL

	HYCOMINE		
	DUPONT	5MG/5ML;25MG/5ML	N19410 001 AUG 17, 1990
	HYCOMINE PEDIATRIC		
	DUPONT	2.5MG/5ML;12.5MG/5ML	N19411 001 AUG 17, 1990

HYDROCORTISONE

CREAM; TOPICAL

	HYDROCORTISONE			
/AT/	/PHARM/BASICS/	/1%/		/N88027/001/ /SEP/27,/1983/
/AT/		/2.5%/		/N88029/001/ /SEP/27,/1983/
	ə PHARM BASICS	1%		N88027 001 SEP 27, 1983
	ə	2.5%		N88029 001 SEP 27, 1983

HYDROCORTISONE

CREAM; TOPICAL

	/HYDROTEX/			
/AT/	/SYOSSET/	/1%/		/N87427/001/ /APR/04,/1988/
	HOGENIC HC			
AT	SYOSSET	1%		N87427 001 APR 04, 1988

OINTMENT; TOPICAL

	HYDROCORTISONE			
/AT/	/PHARM/BASICS/	/1%/		/N88061/001/ /SEP/27,/1983/
/AT/		/2.5%/		/N88039/001/ /SEP/27,/1983/
	ə PHARM BASICS	1%		N88061 001 SEP 27, 1983
	ə	2.5%		N88039 001 SEP 27, 1983

TABLET; ORAL

	/HYCORTOLE/		> DLT >	
/BP/	/VITARINE/	/20MG/	> DLT >	/N80642/002/
	ə VITARINE	20MG	> ADD >	N80642 002
	HYDROCORTISONE			
/BP/	/ANABOLIC/	/20MG/		/N83140/001/
	ə ANABOLIC	20MG		N83140 001

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SUSPENSION; OTIC

	PEDIOTIC			
AT	BURROUGHS WELLCOME	1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML		N62822 001 SEP 29, 1987
	/PEDIOTIC CORTISPORIN/			
/AT/	/BURROUGHS/WELLCOME/	/1%;EQ 3.5MG BASE/ML; 10,000 UNITS/ML/		/N62822/001/ /SEP/29,/1987/

HYDROXYZINE HYDROCHLORIDE

INJECTABLE; INJECTION

	HYDROXYZINE HCL			
/AP/	/SOLOPAK/	/25MG/ML/		/N87592/001/
	ə SOLOPAK	25MG/ML		N87592 001

IBUPROFEN

TABLET; ORAL

	IBUPROFEN		
/AB/	/MCNEIL/	/400MG/	/N70081/001/ /JUN/16,/1986/
/AB/		/600MG/	/N70476/001/ /JUN/16,/1986/
	∂ MCNEIL	400MG	N70081 001 JUN 16, 1986
	∂	600MG	N70476 001 JUN 16, 1986
/AB/	/SUPERPHARM/	/400MG/	/N70708/001/ /APR/25,/1986/
BX	SUPERPHARM	400MG	N70708 001 APR 25, 1986

IDARUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

	IDAMYCIN		
	ADRIA	5MG/VIAL*	N50661 002 SEP 27, 1990
		10MG/VIAL*	N50661 001 SEP 27, 1990

IFOSFAMIDE

INJECTABLE; INJECTION

	IFEX		
	/BRISTOL/MYERS/SQUIBB/3GM/VIAL/		/N19763/002/ /DEC/30,/1988/
	∂ BRISTOL MYERS SQUIBB 3GM/VIAL		N19763 002 DEC 30, 1988

IMIPRAMINE HYDROCHLORIDE

TABLET; ORAL

	IMIPRAMINE HCL			
AB	MUTUAL PHARM	10MG*	N81048 001 JUN 05, 1990	>ADD<
AB		25MG*	N81049 001 JUN 05, 1990	>ADD<
AB		50MG*	N81050 001 JUN 05, 1990	>ADD<

INDOMETHACIN

CAPSULE; ORAL

	INDOMETHACIN		
/BX/	/VITARINE/	/25MG/	/N71711/001/ /JUL/05,/1988/
/BX/		/50MG/	/N71712/001/ /JUL/05,/1988/
	∂ VITARINE	25MG	N71711 001 JUL 05, 1988
	∂	50MG	N71712 001 JUL 05, 1988
/AB/	/ZENITH/	/25MG/	/N18730/001/ /MAY/04,/1984/
/AB/		/50MG/	/N18730/002/ /MAY/04,/1984/
	∂ ZENITH	25MG	N18730 001 MAY 04, 1984
	∂	50MG	N18730 002 MAY 04, 1984

CAPSULE, EXTENDED RELEASE; ORAL

	INDOMETHACIN		
/BX/	/VITARINE/	/75MG/	/N71531/001/ /JUL/21,/1987/
	∂ VITARINE	75MG	N71531 001 JUL 21, 1987

IODOHIPPURATE SODIUM, I-131

INJECTABLE; INJECTION

	IODOHIPPURATE SODIUM I 131		
	CIS /SORIN/	0.2MCI/ML /0.2MCI/ML/	N17313 001 /N17313/001/

IOTHALAMATE SODIUM

INJECTABLE; INJECTION

	CONRAY 325		
	MALLINCKRODT	54.3%	N17685 001
	CONRAY 400		
	MALLINCKRODT	66.8%	N14295 001
	/CONRAY-325/		
	/MALLINCKRODT/	/54.3%/	/N17685/001/
	/CONRAY-400/		
	/MALLINCKRODT/	/66.8%/	/N14295/001/

ISOETHARINE HYDROCHLORIDE

SOLUTION; INHALATION

	ISOETHARINE HCL		
AN	DEY LABS	0.08%	N88187 001 DEC 03, 1982
		/0.08%/	/N88187/001/ /DEC/03,/1982/
AN	INTL MEDTN SYS	0.08% /0.0833%/	N86651 002 /N86651/002/
	ISOETHARINE HCL S/F		
AN	DEY LABS	0.08%	N89817 001 NOV 22, 1988
		/0.08%/	/N89817/001/ /NOV/22,/1988/

ISONIAZID

TABLET; ORAL

	ISONIAZID		
/AA/	/ANABOLIC/	/100MG/	/N84050/001/
	∂ ANABOLIC	100MG	N84050 001
/AA/	/PUREPAC/PHARM/	/50MG/	/N80132/003/ /JUL/14,/1982/
/AA/		/100MG/	/N80132/004/ /JUL/14,/1982/
	∂ PUREPAC PHARM	50MG	N80132 003 JUL 14, 1982
	∂	100MG	N80132 004 JUL 14, 1982

ISOPROTERENOL HYDROCHLORIDE

INJECTABLE; INJECTION

	ISOPROTERENOL HCL			
>DLT< /AP/	/LYPHOMED/	/0.2MG/ML/	/N83431/001/	
>ADD<	∂ LYPHOMED	0.2MG/ML	N83431 001	

ISOSORBIDE DINITRATE

TABLET; ORAL

	ISOSORBIDE DINITRATE		
/AB/	/SUPERPHARM/	/5MG/	/N89190/001/ /FEB/17,/1987/
/AB/		/10MG/	/N89191/001/ /FEB/17,/1987/
/AB/		/20MG/	/N89192/001/ /FEB/17,/1987/
	∂ SUPERPHARM	5MG	N89190 001 FEB 17, 1987
	∂	10MG	N89191 001 FEB 17, 1987
	∂	20MG	N89192 001 FEB 17, 1987

KANAMYCIN SULFATE

INJECTABLE; INJECTION

	KANAMYCIN SULFATE		
/AP/	/WARNER/CHILCOTT/	/EQ 1GM BASE/3ML/	/N63092/001/ /OCT/11,/1989/
	∂ WARNER CHILCOTT	EQ 1GM BASE/3ML	N63092 001 OCT 11, 1989

KETOCONAZOLE

SHAMPOO; TOPICAL

	NIZORAL		
	JANSSEN RES	2%*	N19927 001 AUG 31, 1990

LEUPROLIDE ACETATE

INJECTABLE; INJECTION

	/LUPRON/DEPOT/		
	/TAKEDA/ABBOTT/	/3.75MG/VIAL/	/N19732/001/ /JAN/26,/1989/
	LUPRON DEPOT		
	TAP PHARMS	3.75MG/VIAL*	N20011 001 OCT 22, 1990
		7.5MG/VIAL	N19732 001 JAN 26, 1989

LEVAMISOLE HYDROCHLORIDE

TABLET; ORAL

ERGAMISOL			
JANSSEN	EQ 50MG BASE*	N20035 001	
		JUN 18, 1990	

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION

LIDOCAINE HCL				
/AP/	/ABBOTT/	/1.5%/	/N88330/001/	
			/MAY/17,/1984/	
∂ ABBOTT		1.5%	N88330 001	
			MAY 17, 1984	
/AP/	/LYPHOMED/	/1%/	/N80420/003/	
/AP/		/1.5%/	/N80420/005/	
/AP/		/2%/	/N80420/002/	
∂ LYPHOMED		1%	N80420 003	
∂		1.5%	N80420 005	
∂		2%	N80420 002	

LINDANE

LOTION; TOPICAL

/GAMENE/			
/AT/ /BARNES/HIND/	/1%/	/N84989/001/	
∂ BARNES HIND	1%	N84989 001	

SHAMPOO; TOPICAL

/GAMENE/			
/AT/ /BARNES/HIND/	/1%/	/N84988/001/	
∂ BARNES HIND	1%	N84988 001	

MANNITOL; SORBITOL

SOLUTION; IRRIGATION

SORBITOL-MANNITOL				
/AT/	/ABBOTT/	/540MG/100ML;/ /2.7GM/100ML/	/N80224/001/	
∂ ABBOTT		540MG/100ML; 2.7GM/100ML	N80224 001	

MANNITOL; SORBITOL

SOLUTION; IRRIGATION

SORBITOL-MANNITOL IN PLASTIC CONTAINER				
/AT/	/ABBOTT/	/540MG/100ML;/ /2.7GM/100ML/	/N17636/001/	
/AT/		/540MG/100ML;/ /2.7GM/100ML/	/N18316/001/	
ABBOTT		540MG/100ML; 2.7GM/100ML	N17636 001	
		540MG/100ML; 2.7GM/100ML	N18316 001	

MEBUTAMATE

/TABLET;/ORAL/			
/DORMATE/			
/WALLACE/	/600MG/		/N17374/001/
∂ WALLACE	600MG		N17374 001

MECLIZINE HYDROCHLORIDE

TABLET; ORAL

MECLIZINE HCL				
/AA/	/ANABOLIC/	/25MG/	/N85891/001/	
∂ ANABOLIC		25MG	N85891 001	
/AA/	/CAMALI/	/12.5MG/	/N84464/001/	
/AA/		/25MG/	/N84713/001/	
/AA/	/SUPERPHARM/	/12.5MG/	/N89113/001/ /AUG/20,/1985/	
/AA/		/25MG/	/N89114/001/ /AUG/20,/1985/	
∂ SUPERPHARM		12.5MG	N89113 001 AUG 20, 1985	
∂		25MG	N89114 001 AUG 20, 1985	

TABLET, CHEWABLE; ORAL

MECLIZINE HCL				
/AA/	/ANABOLIC/	/25MG/	/N86392/001/	
∂ ANABOLIC		25MG	N86392 001	

MECLOFENAMATE SODIUM

CAPSULE; ORAL

MECLOFENAMATE SODIUM				
/BX/	/BOLAR/PHARM/	/EQ/50MG/BASE/	/N70400/001/ /NOV/25,/1986/	
/BX/		/EQ/100MG/BASE/	/N70401/001/ /NOV/25,/1986/	
∂ BOLAR PHARM		EQ 50MG BASE	N70400 001 NOV 25, 1986	
∂		EQ 100MG BASE	N70401 001 NOV 25, 1986	
/BX/	/VITARINE/	/EQ/50MG/BASE/	/N71710/001/ /JUN/15,/1988/	
/BX/		/EQ/100MG/BASE/	/N71684/001/ /JUN/15,/1988/	
∂ VITARINE		EQ 50MG BASE	N71710 001 JUN 15, 1988	
∂		EQ 100MG BASE	N71684 001 JUN 15, 1988	

MEFENAMIC ACID

CAPSULE; ORAL

/MEFENAMIC/ACID/				
/BX/	/VITARINE/	/250MG/	/N72179/001/ /APR/21,/1988/	
∂ VITARINE		250MG	N72179 001 APR 21, 1988	
PONSTEL				
/AB/	/PARKE/DAVIS/	/250MG/	/N15034/003/	
AB	PARKE DAVIS	250MG	N15034 003	

MEGESTROL ACETATE

TABLET; ORAL

MEGESTROL ACETATE				
/AB/	/PBI/	/20MG/	/N70646/001/ /OCT/02,/1987/	
/AB/		/40MG/	/N70647/001/ /OCT/02,/1987/	
BX	PBI	20MG	N70646 001 OCT 02, 1987	
BX		40MG	N70647 001 OCT 02, 1987	

MEPERIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

MEPERIDINE HCL				
/AP/	/INTL/MEDTN/SYS/	/10MG/ML/	/N86332/001/	
∂ INTL MEDTN SYS		10MG/ML	N86332 001	

MEPROBAMATE

TABLET; ORAL

MEPROBAMATE				
/AA/	/ANABOLIC/	/200MG/	/N84220/001/	
/AA/		/400MG/	/N84589/002/	
∂ ANABOLIC		200MG	N84220 001	
∂		400MG	N84589 002	
/AA/	/PRIVATE/FMLTNS/	/400MG/	/N14601/001/	
∂ PRIVATE FMLTNS		400MG	N14601 001	
/AA/	/REID/ROWELL/	/200MG/	/N84435/001/	
∂ REID ROWELL		200MG	N84435 001	

MESTRANOL; NORETHINDRONE

TABLET; ORAL-21

NORETHIN 1/50M-21				
AB	SCHIAPPARELLI SEARLE	0.05MG;1MG		N71539 001 APR 12, 1988
/AB/	/SEARLE/	/0.05MG;1MG/	/N71539/001/ /APR/12,/1988/	
/NORINYL/1+80/21-DAY/				
/SYNTEX/(FP)/		/0.08MG;1MG/	/N16724/001/	
∂ SYNTEX (FP)		0.08MG;1MG	N16724 001	

TABLET; ORAL-28

NORETHIN 1/50M-28				
AB	SCHIAPPARELLI SEARLE	0.05MG;1MG		N71540 001 APR 12, 1988
/AB/	/SEARLE/	/0.05MG;1MG/	/N71540/001/ /APR/12,/1988/	
/NORINYL/1+80/28-DAY/				
/SYNTEX/(FP)/		/0.08MG;1MG/	/N16725/001/	
∂ SYNTEX (FP)		0.08MG;1MG	N16725 001	

METAPROTERENOL SULFATE

TABLET; ORAL

METAPROTERENOL SULFATE				
AB	BIOCRAFT LABS	10MG*		N72519 001 MAR 30, 1990
AB		20MG*		N72520 001 MAR 30, 1990

METHARBITAL

/TABLET;/ORAL/
/GEMONIL/
/ABBOTT/ /100MG/ /N08322/001/
∂ ABBOTT 100MG N08322 001

METHICILLIN SODIUM

INJECTABLE; INJECTION
STAPHCILLIN
/BRISTOL/ /EQ/900MG/BASE/VIAL/ /N50117/001/
∂ BRISTOL EQ 900MG BASE/VIAL N50117 001
∂ /EQ/3.6GM/BASE/VIAL/ /N50117/002/
EQ 3.6GM BASE/VIAL N50117 002
∂ /EQ/5.4GM/BASE/VIAL/ /N50117/003/
EQ 5.4GM BASE/VIAL N50117 003

METHOTREXATE SODIUM

TABLET; ORAL
METHOTREXATE
AB BARR EQ 2.5MG BASE‡ N81099 001 OCT 15, 1990
AB LEDERLE EQ 2.5MG BASE N08085 002

METHYCLOTHIAZIDE; PARGYLINE HYDROCHLORIDE

>DLT> /TABLET;/ORAL/
>DLT> /EUTRON/
>DLT> /ABBOTT/ /5MG;25MG/ /N16047/001/
>ADD> ∂ ABBOTT 5MG;25MG N16047 001

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE; INJECTION
METHYLPREDNISOLONE SODIUM SUCCINATE
/AP/ /INTL/MEDICATION/ /EQ 40MG BASE/VIAL/ /N87812/001/ /FEB/09,/1983/
/AP/ /EQ 125MG BASE/VIAL/ /N87813/001/ /FEB/09,/1983/
/AP/ /EQ 500MG BASE/VIAL/ /N87851/001/ /FEB/09,/1983/
/AP/ /EQ 1GM BASE/VIAL/ /N87852/001/ /FEB/09,/1983/
∂ INTL MEDICATION EQ 40MG BASE/VIAL N87812 001 FEB 09, 1983
∂ EQ 125MG BASE/VIAL N87813 001 FEB 09, 1983
∂ EQ 500MG BASE/VIAL N87851 001 FEB 09, 1983
∂ EQ 1GM BASE/VIAL N87852 001 FEB 09, 1983

METHYLTESTOSTERONE

TABLET; ORAL
METHYLTESTOSTERONE
>DLT> /BP/ /KV/ /10MG/ /N84312/001/
>ADD> ∂ KV 10MG N84312 001
/BP/ /WEST/WARD/ /25MG/ /N84642/001/
∂ WEST WARD 25MG N84642 001

METIPRANOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC
/METIPRANOLOL/HCL/
/BAUSCH/AND/LOMB/ /0.3%/ /N19907/001/ /DEC/29,/1989/
OPTIPRANOLOL
BAUSCH AND LOMB 0.3% N19907 001 DEC 29, 1989

METOCLOPRAMIDE HYDROCHLORIDE

INJECTABLE; INJECTION
REGLAN
/ROBINS/ /EQ/10MG/BASE/ML/ /N17862/004/ /MAY/28,/1987/
∂ ROBINS EQ 10MG BASE/ML N17862 004 MAY 28, 1987

METOCLOPRAMIDE HYDROCHLORIDE

TABLET; ORAL
METOCLOPRAMIDE HCL
AB CORD EQ 10MG BASE‡ N72215 001 JAN 30, 1990
AB MARTEC EQ 10MG BASE N70598 001 FEB 02, 1987
/∂/ /EQ/10MG/BASE/ /N70598/001/ /FEB/02,/1987/

MINOCYCLINE HYDROCHLORIDE

CAPSULE; ORAL
MINOCIN
AB LEDERLE EQ 50MG BASE‡ N50649 001 MAY 31, 1990
AB EQ 100MG BASE‡ N50649 002 MAY 31, 1990
/EQ/50MG/BASE/ /N50315/002/
∂ EQ 50MG BASE N50315 002
/EQ/50MG/BASE‡/ /N50649/001/ /MAY/31,/1990/
/EQ/100MG/BASE/ /N50315/001/
∂ EQ 100MG BASE N50315 001
/EQ/100MG/BASE‡/ /N50649/002/ /MAY/31,/1990/

MINOCYCLINE HCL
AB WARNER CHILCOTT EQ 50MG BASE‡ N63066 001 AUG 14, 1990
AB EQ 100MG BASE‡ N63067 001 JUL 31, 1990

/TABLET;/ORAL/
/MINOCIN/
/LEDERLE/ /EQ/50MG/BASE/ /N50451/003/ /AUG/10,/1982/
/EQ/100MG/BASE/ /N50451/002/ /AUG/10,/1982/
∂ LEDERLE EQ 50MG BASE N50451 003 AUG 10, 1982
∂ EQ 100MG BASE N50451 002 AUG 10, 1982

MISOPROSTOL

TABLET; ORAL
CYTOTEC
SEARLE 0.1MG‡ N19268 003 SEP 21, 1990

MORICIZINE HYDROCHLORIDE

TABLET; ORAL
ETHMOZINE
DUPONT 200MG‡ N19753 001 JUN 19, 1990
250MG‡ N19753 002 JUN 19, 1990
300MG‡ N19753 003 JUN 19, 1990

MORPHINE SULFATE

INJECTABLE; INJECTION
MORPHINE SULFATE
SURVIVAL TECH 15MG/ML‡ N19999 001 JUL 12, 1990

TABLET, EXTENDED RELEASE; ORAL
MS CONTIN
PURDUE FREDERICK 100MG‡ N19516 004 JAN 16, 1990

NAFARELIN ACETATE

SPRAY, METERED; NASAL
SYNAREL
SYNTEX EQ 2MG BASE/ML‡ N19886 001 FEB 13, 1990

NAFTIFINE HYDROCHLORIDE

GEL; TOPICAL
NAFTIN
ALLERGAN 1%‡ N19356 001 JUN 18, 1990

NAPROXEN SODIUM

TABLET; ORAL
/ANAPROX/
/SYNTEX/ /550MG/ /N18164/003/ /SEP/30,/1987/
ANAPROX DS
SYNTEX 550MG N18164 003 SEP 30, 1987

NIFEDIPINE

CAPSULE; ORAL

NIFEDIPINE

AB	CHASE LABS	10MG	N72409 001 SEP 04, 1990 : JUL 10, 1989
AB	PUREPAC PHARM	10MG	N72579 001 APR 28, 1989
AB		20MG¤	N72556 001 SEP 20, 1990 : APR 28, 1989

NITROGLYCERIN

INJECTABLE; INJECTION

NITRO-BID

AP	MARION MERRELL DOW	10MG/ML¤	N71159 001 FEB 28, 1990

NITROGLYCERIN IN DEXTROSE 5%

AP	ABBOTT LABS	10MG/100ML¤	N71846 001 AUG 31, 1990
AP		20MG/100ML¤	N71847 001 AUG 31, 1990
AP		40MG/100ML¤	N71848 001 AUG 31, 1990
AP	BAXTER	10MG/100ML	N19970 001 DEC 29, 1989
AP		20MG/100ML	N19970 002 DEC 29, 1989
AP		40MG/100ML	N19970 003 DEC 29, 1989

/NITROGLYCERIN/100MG/IN/DEXTROSE/5%/ /BAXTER/ /40MG/100ML/ /N19970/003/ /DEC/29,/1989/

/NITROGLYCERIN/25MG/IN/DEXTROSE/5%/ /BAXTER/ /10MG/100ML/ /N19970/001/ /DEC/29,/1989/

/NITROGLYCERIN/50MG/IN/DEXTROSE/5%/ /BAXTER/ /20MG/100ML/ /N19970/002/ /DEC/29,/1989/

OCTREOTIDE ACETATE

INJECTABLE; INJECTION

SANDOSTATIN

	SANDOZ PHARMS	EQ 50UGM BASE/ML	N19667 001 OCT 21, 1988
		EQ 100UGM BASE/ML	N19667 002 OCT 21, 1988
		EQ 500UGM BASE/ML	N19667 003 OCT 21, 1988

OLSALAZINE SODIUM

CAPSULE; ORAL

DIPENTUM

	PHARMACIA	250MG¤	N19715 001 JUL 31, 1990

OMEPRAZOLE

CAPSULE, DELAYED REL PELLETS; ORAL

/LOSEC/

	MS&D RES LABS	20MG	N19810 001 SEP 14, 1989

PRILOSEC

OXAZEPAM

CAPSULE; ORAL

OXAZEPAM

BX	CHELSEA LABS	10MG	N71661 001 MAR 02, 1988
BX		15MG	N71662 001 MAR 02, 1988
BX		30MG	N71663 001 MAR 02, 1988

OXAZEPAM

CAPSULE; ORAL

OXAZEPAM

AB	DANBURY	10MG¤	N72952 001 SEP 28, 1990
AB		15MG¤	N72953 001 SEP 28, 1990
AB		30MG¤	N72954 001 SEP 28, 1990

PANCURONIUM BROMIDE

INJECTABLE; INJECTION

PANCURONIUM BROMIDE

AP	KENDALL MCGAW	1MG/ML¤	N72759 001 JUL 31, 1990
AP		2MG/ML¤	N72760 001 JUL 31, 1990

PEGADEMASE BOVINE

INJECTABLE; INJECTION

ADAGEN

	ENZON	250 UNITS/ML¤	N19818 001 MAR 21, 1990

PENBUTOLOL SULFATE

TABLET; ORAL

LEVATOL

	REED AND CARNRICK	10MG	N18976 001 DEC 30, 1987	> ADD >
		20MG	N18976 004 JAN 05, 1989	> ADD >

/REED/AND/CARNRICK/ /10MG/ /N18976/001/ /DEC/30,/1987/ > DLT >

PENICILLIN G POTASSIUM

INJECTABLE; INJECTION

PENICILLIN G POTASSIUM IN PLASTIC CONTAINER

	BAXTER	20,000 UNITS/ML¤	N50638 001 JUN 25, 1990	> DLT >/AA/
		40,000 UNITS/ML¤	N50638 002 JUN 25, 1990	> ADD >
		60,000 UNITS/ML¤	N50638 003 JUN 25, 1990	

PENTOBARBITAL SODIUM

CAPSULE; ORAL

SODIUM PENTOBARBITAL

AA	ANABOLIC	100MG	N84590 001	
	ANABOLIC	100MG	N84238 001	

/TABLET;/ORAL/ /SODIUM/PENTOBARBITAL/

PERPHENAZINE

TABLET; ORAL

PERPHENAZINE

	CHELSEA	8MG	N89700 001 DEC 23, 1987	

/CHELSEA/ /8MG/ /N89700/001/ /DEC/23,/1987/

PHENAZOPYRIDINE HYDROCHLORIDE; SULFISOXAZOLE

TABLET; ORAL

AZO GANTRISIN

	ROCHE	50MG;500MG	N19358 001 AUG 31, 1990

PHENDIMETRAZINE TARTRATE

TABLET; ORAL

ALPHAZINE

AA	VITARINE	35MG	N85034 001	> DLT >/AA/
	VITARINE	35MG	N85830 001	> DLT >/AA/
	VITARINE	35MG	N85034 001	> ADD >
	VITARINE	35MG	N85830 001	> ADD >

PHENDIMETRAZINE TARTRATE

PHENTERMINE HYDROCHLORIDE

TABLET; ORAL

PHENTERMINE HCL

AA	VITARINE	8MG	N85671 001	> DLT >/AA/
AA	VITARINE	8MG	N85689 001	> DLT >/AA/
	VITARINE	8MG	N85671 001	> ADD >
		8MG	N85689 001	> ADD >

PHENTERMINE RESIN COMPLEX

CAPSULE, EXTENDED RELEASE; ORAL

IONAMIN-15				
	FISONS	EQ 15MG BASE	N11613 004	
/PENNWALT/	/EQ/15MG/BASE/	/N11613/004/		
IONAMIN-30				
	FISONS	EQ 30MG BASE	N11613 002	
/PENNWALT/	/EQ/30MG/BASE/	/N11613/002/		

PHENYTOIN SODIUM

INJECTABLE; INJECTION

PHENYTOIN SODIUM

/AP/	/WARNER/CHILCOTT/	/50MG/ML¤/	/N89900/001/		
			/MAR/30,/1990/		
	ə WARNER CHILCOTT	50MG/ML¤	N89900 001		
			MAR 30, 1990		

PHENYTOIN SODIUM, EXTENDED

CAPSULE; ORAL

EXTENDED PHENYTOIN SODIUM

/AB/	/SIDMAK/	/100MG/	/N89441/001/		
			/DEC/18,/1986/		
	ə SIDMAK	100MG	N89441 001		
			DEC 18, 1986		
	PHENYTEX				
/BX/	/BOLAR/	/100MG¤/	/N88711/001/	>_DLT_>/AP/	/LYPHOMED/
			/DEC/21,/1984/	>_ADD_>	ə LYPHOMED
	ə BOLAR	100MG¤	N88711 001		
			DEC 21, 1984		

PHYTONADIONE

INJECTABLE; INJECTION

VITAMIN K1

/BP/	/ABBOTT/	/10MG/ML/	/N87956/001/
			/JUL/25,/1983/
	ə ABBOTT	10MG/ML	N87956 001
			JUL 25, 1983

PIPECURONIUM BROMIDE

INJECTABLE; INJECTION

ARDUAN

ORGANON	1MG/ML¤	N19638 001
		JUN 26, 1990

PIPERAZINE CITRATE

SYRUP; ORAL

	/BRYREL/			
/AA/	/STERLING/	/EQ 500MG BASE/5ML/	/N17796/001/	
	ə STERLING	EQ 500MG BASE/5ML	N17796 001	

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE, ANHYDROUS

POWDER FOR RECONSTITUTION; ORAL

GLYCOPREP

AA	SUPERPHARM	236GM/BOT;2.97GM/BOT;6.74GM/BOT;		
		5.86GM/BOT;22.74GM/BOT	N72319 001	
			DEC 23, 1988	
/AA/	/TOSA/MEDCL/	/236GM/BOT;2.97GM/BOT;6.74GM/BOT;/		
		/5.86GM/BOT;22.74GM/BOT/	/N72319/001/	
			/DEC/23,/1988/	

POTASSIUM CHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

K-LEASE

AB	ADRIA	10 MEQ¤	N72427 001
			MAR 28, 1990

INJECTABLE; INJECTION

POTASSIUM CHLORIDE

>_DLT_>/AP/	/LYPHOMED/	/2MEQ/ML/	/N80204/001/		
>_ADD_>	ə LYPHOMED	2MEQ/ML	N80204 001		

PREDNISOLONE

TABLET; ORAL

PREDNISOLONE

/BX/	/SUPERPHARM/	/5MG/	/N88892/001/
			/FEB/26,/1985/
	ə SUPERPHARM	5MG	N88892 001
			FEB 26, 1985
/BX/	/UDL/	/5MG/	/N87987/001/
			/JAN/18,/1983/
	ə UDL	5MG	N87987 001
			JAN 18, 1983

PREDNISOLONE ACETATE

INJECTABLE; INJECTION

PREDNISOLONE ACETATE

/BP/	/AKORN/	/25MG/ML/	/N83032/001/
	ə AKORN	25MG/ML	N83032 001

PREDNISOLONE SODIUM PHOSPHATE

SOLUTION/DROPS; OPHTHALMIC

	/METRETON/		
	/SCHERING/	/EQ/0.5%/PHOSPHATE/	/N83834/001/
	ə SCHERING	EQ 0.5% PHOSPHATE	N83834 001

PREDNISONE

TABLET; ORAL

PREDNISONE

/AB/	/PRIVATE/FMLTNS/	/20MG/	/N85151/001/		
	ə PRIVATE FMLTNS	20MG	N85151 001		
/BX/	/UDL/LABS/	/5MG/	/N87984/001/		
			/JAN/18,/1983/		
/BX/		/10MG/	/N87985/001/		
			/JAN/18,/1983/		
/BX/		/20MG/	/N87986/001/		
			/JAN/18,/1983/		
	ə UDL LABS	5MG	N87984 001		
			JAN 18, 1983		
	ə	10MG	N87985 001		
			JAN 18, 1983		
	ə	20MG	N87986 001		
			JAN 18, 1983		

PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PROMETHAZINE HCL

>_DLT_>/AA/	/KV/PHARM/	/6.25MG/5ML/	/N85388/001/	
>_DLT_>/AA/		/25MG/5ML/	/N85385/001/	
>_ADD_>	ə KV PHARM	6.25MG/5ML	N85388 001	
>_ADD_>	ə	25MG/5ML	N85385 001	

TABLET; ORAL

PROMETHAZINE HCL

>_DLT_> /BP/	/PRIVATE/FMLTNS/	/12.5MG/	/N83214/001/	
>_ADD_>	ə PRIVATE FMLTNS	12.5MG	N83214 001	

PROPANTHELINE BROMIDE

TABLET; ORAL

PROPANTHELINE BROMIDE

/AA/	/PRIVATE/FMLTNS/	/15MG/	/N80977/001/
	ə PRIVATE FMLTNS	15MG	N80977 001

PROPOXYPHENE HYDROCHLORIDE

CAPSULE; ORAL

PROPOXYPHENE HCL

/AA/	/ANABOLIC/	/65MG/	/N83185/001/
	ə ANABOLIC	65MG	N83185 001
/AA/	/PRIVATE/FMLTNS/	/32MG/	/N83464/001/
/AA/		/65MG/	/N83113/001/
	ə PRIVATE FMLTNS	32MG	N83464 001
	ə	65MG	N83113 001

PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL

INDERAL

/AB/	/WYETH/AYERST/LABS/	/90MG/	/N16418/010/
			/OCT/18,/1982/
	ə WYETH AYERST LABS	90MG	N16418 010
			OCT 18, 1982

PROPRANOLOL

/AB/	/MYLAN/PHARMS/	/10MG/	/N70211/001/
			/NOV/19,/1985/
/AB/		/20MG/	/N70212/001/
			/NOV/19,/1985/
/AB/		/40MG/	/N70213/001/
			/NOV/19,/1985/
/AB/		/80MG/	/N70214/001/
			/NOV/19,/1985/

PROPRANOLOL HCL

/AB/	/DANBURY/PHARMA/	/90MG/	/N71183/001/
			/OCT/06,/1986/
	ə DANBURY PHARMA	90MG	N71183 001
			OCT 06, 1986

PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL
PROPRANOLOL HCL

AB	MARTEC	10MG	N70120 001 AUG 06, 1985	
AB		20MG	N70121 001 AUG 06, 1985	
AB		40MG	N70122 001 AUG 06, 1985	
AB		60MG	N70123 001 OCT 29, 1986	
AB		80MG	N70124 001 AUG 06, 1985	
/AB/	/MYLAN/	/10MG/	/N70120/001/ /AUG/06,/1985/	> ADD >
/AB/	/MYLAN/	/20MG/	/N70121/001/ /AUG/06,/1985/	> ADD >
/AB/	/MYLAN/	/40MG/	/N70122/001/ /AUG/06,/1985/	> ADD >
/AB/	/MYLAN/	/60MG/	/N70123/001/ /OCT/29,/1986/	> ADD >
/AB/	/MYLAN/	/80MG/	/N70124/001/ /AUG/06,/1985/	> ADD >
AB	MYLAN	10MG	N70211 001 NOV 19, 1985	
AB		20MG	N70212 001 NOV 19, 1985	
AB		40MG	N70213 001 NOV 19, 1985	
AB		80MG	N70214 001 NOV 19, 1985	

PROPYLTHIOURACIL

TABLET; ORAL
PROPYLTHIOURACIL

/BP/	/ANABOLIC/	/50MG/	/N80285/001/	
	ə ANABOLIC	50MG	N80285 001	

PROTEIN HYDROLYSATE

INJECTABLE; INJECTION
AMINOSOL 5%

/ABBOTT/	/5%/	/N05932/012/ /JAN/31,/1985/	
ə ABBOTT	5%	N05932 012 JAN 31, 1985	

PROTEIN HYDROLYSATE

/INJECTABLE;/INJECTION/
/HYDROTIGEN 5%/

/AP/	/KENDALL/MCGAW/	/5%/	/N06170/003/ /JAN/10,/1984/	
	ə KENDALL MCGAW	5%	N06170 003 JAN 10, 1984	

PYRIDOSTIGMINE BROMIDE

TABLET; ORAL
PYRIDOSTIGMINE BROMIDE

	PUREPAC	30MG	N89572 001 NOV 27, 1990

QUAZEPAM

TABLET; ORAL
DORMALIN

	BAKER CUMMINS	7.5MG	N18708 003 FEB 26, 1987
		15MG	N18708 001 DEC 27, 1985
/SCHERING/		/7.5MG/	/N18708/003/ /FEB/26,/1987/
		/15MG/	/N18708/001/ /DEC/27,/1985/

QUINIDINE GLUCONATE

TABLET, EXTENDED RELEASE; ORAL
QUINIDINE GLUCONATE

/AB/	/SUPERPHARM/	/324MG/	/N89164/001/ /NOV/21,/1985/	
	ə SUPERPHARM	324MG	N89164 001 NOV 21, 1985	

QUINIDINE SULFATE

TABLET; ORAL
QUINIDINE SULFATE

/AB/	/LEDERLE/	/200MG/	/N86176/001/ N86176 001	
	ə LEDERLE	200MG		

RAUWOLFIA SERPENTINA

TABLET; ORAL
/WOLFINA/

/BP/	/FOREST/	/100MG/	/N09255/006/	
	ə FOREST	100MG	N09255 006	

SARALASIN ACETATE

/INJECTABLE;/INJECTION/
/SARENIN/

/NORWICH/EATON/	/EQ/0.6MG/BASE/ML/	/N18009/001/	
ə NORWICH EATON	EQ 0.6MG BASE/ML	N18009 001	

SECOBARBITAL SODIUM

CAPSULE; ORAL
SODIUM SECOBARBITAL

/AA/	/KV/	/100MG/	/N85285/001/	> DLT >/> ADD >
	ə KV	100MG	N85285 001	

INJECTABLE; INJECTION
/SECONAL SODIUM/

/LILLY/	/50MG/ML/	/N07392/002/	
ə LILLY	50MG/ML	N07392 002	

SODIUM CHLORIDE

INJECTABLE; INJECTION
SODIUM CHLORIDE

/ABBOTT/	/20GM/100ML/	/N17013/001/	
ə ABBOTT	20GM/100ML	N17013 001	

SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER

AP	BAXTER	450MG/100ML	N18016 001

/SODIUM CHLORIDE 0.45% IN WATER IN PLASTIC CONTAINER/

/BAXTER/	/450MG/100ML/	/N18016/001/	

SODIUM CHLORIDE 3% IN PLASTIC CONTAINER

/BAXTER/	/3GM/100ML/	/N19022/001/ /NOV/01,/1983/	
BAXTER	3GM/100ML	N19022 001 NOV 01, 1983	
/KENDALL/MCGAW/	/3GM/100ML/	/N19635/003/ /MAR/09,/1988/	
ə KENDALL MCGAW	3GM/100ML	N19635 003 MAR 09, 1988	

SODIUM CHLORIDE 5% IN PLASTIC CONTAINER

/BAXTER/	/5GM/100ML/	/N19022/002/ /NOV/01,/1983/	
BAXTER	5GM/100ML	N19022 002 NOV 01, 1983	

SODIUM CHLORIDE

INJECTABLE; INJECTION
SODIUM CHLORIDE 5% IN PLASTIC CONTAINER

/AP/	/KENDALL/MCGAW/	/5GM/100ML/	/N19635/004/ /MAR/09,/1988/	
	ə KENDALL MCGAW	5GM/100ML	N19635 004 MAR 09, 1988	

SOYBEAN OIL

INJECTABLE; INJECTION
LIPOSYN III 10%

AP	ABBOTT	10%	N18969 001 SEP 24, 1984
/S/		/10%/	/N18969/001/ /SEP/24,/1984/

LIPOSYN III 20%

AP	ABBOTT	20%	N18970 001 SEP 25, 1984
/S/		/20%/	/N18970/001/ /SEP/25,/1984/

/TRAVAMULSION 20%/

/BAXTER/	/20%/	/N18758/001/ /FEB/15,/1983/	
ə BAXTER	20%	N18758 001 FEB 15, 1983	

SULFAMETHIZOLE

TABLET; ORAL
/MICROSUL/

/FOREST/	/1GM/	/N86012/001/	
ə FOREST	1GM	N86012 001	

SULFAMETHOXAZOLE; TRIMETHOPRIM

SUSPENSION; ORAL
/SULFAMETH PEDIATRIC/

/AB/	/PHARM BASICS/	/200MG/5ML;40MG/5ML/	/N70064/001/ /AUG/01,/1986/	
	ə PHARM BASICS	200MG/5ML;40MG/5ML	N70064 001 AUG 01, 1986	

SULFASALAZINE

TABLET; ORAL
/S.A.S.-500/

/AB/	/REID/ROWELL/	/500MG/	/N83456/001/

SULFASALAZINE

TABLET; ORAL
/S.A.S.-500/
ə REID ROWELL 500MG N83450 001
SULFASALAZINE
> DLT > /BP/ /VITARINE/ /500MG/ /N86184/001/
> ADD > ə VITARINE 500MG N86184 001

SULFISOXAZOLE

TABLET; ORAL
/SULFOXIN/
/AB/ /REID/ROWELL/ /500MG/ /N80040/001/
ə REID ROWELL 500MG N80040 001

SULINDAC

TABLET; ORAL
SULINDAC
/AB/ /AM/THERAP/ /150MG/ /N72171/001/
/APR/03,/1990/:/MAY/23,/1990/
/AB/ /200MG/ /N72172/001/
/APR/03,/1990/:/MAY/23,/1990/

TECHNETIUM TC-99M ALBUMIN AGGREGATED KIT

INJECTABLE; INJECTION
AN-MAA
BS CIS N/A N17792 001
/BS/ /SORIN/ /N/A/ /N17792/001/

TECHNETIUM TC-99M MERTIATIDE KIT

INJECTABLE; INJECTION
TECHNESCAN MAG3
MALLINCKRODT N/A* N19882 001
JUN 15, 1990

TECHNETIUM TC-99M PENTETATE KIT

INJECTABLE; INJECTION
AN-DTPA
AP CIS N/A N17714 001
/AP/ /SYNCOR/ /N/A/ /N17714/001/

TECHNETIUM TC-99M SODIUM PERTECHNETATE

SOLUTION; INJECTION, ORAL
SODIUM PERTECHNETATE TC 99M
/MEDI/PHYSICS/ /2-100MCI/ML/ /N17471/001/
ə MEDI PHYSICS 2-100MCI/ML N17471 001

TETRACYCLINE HYDROCHLORIDE

CAPSULE; ORAL
TETRACYCLINE HCL
/BX/ /VITARINE/ /250MG/ /N61471/001/
/BX/ /500MG/ /N61471/002/
/SEP/06,/1988/
ə VITARINE 250MG N61471 001
ə 500MG N61471 002
SEP 06, 1988

TETRACYCLINE PHOSPHATE COMPLEX

CAPSULE; ORAL
TETREX
/BRISTOL/ /EQ/250MG/HCL/ /N50212/002/
ə BRISTOL EQ 250MG HCL N50212 002
/EQ/500MG/HCL/ /N50212/003/
ə EQ 500MG HCL N50212 003

THEOPHYLLINE

CAPSULE, EXTENDED RELEASE; ORAL
THEOPHYL-SR
/BC/ /JOHNSON/RW/ /250MG/ /N86471/001/
/FEB/08,/1985/
ə JOHNSON RW 250MG N86471 001
FEB 08, 1985
THEOPHYLLINE
> DLT > /BC/ /VITARINE/ /260MG/ /N87462/001/
> DLT > /MAY/11,/1982/
> ADD > ə VITARINE 260MG N87462 001
> ADD > MAY 11, 1982

TABLET, EXTENDED RELEASE; ORAL
THEOCHRON
AB INWOOD 100MG N88320 001
FEB 21, 1985
AB 200MG N88321 001
FEB 21, 1985
AB 300MG N87400 002
JAN 11, 1983

THEOPHYLLINE

TABLET, EXTENDED RELEASE; ORAL
/THEOPHYLLINE/
/AB/ /INWOOD/ /100MG/ /N88320/001/
/FEB/21,/1985/
/AB/ /200MG/ /N88321/001/
/FEB/21,/1985/
/AB/ /300MG/ /N87400/002/
/JAN/11,/1983/
THEOPHYLLINE
AB SIDMAK 100MG* N89807 001
APR 30, 1990
AB 200MG* N89808 001
APR 30, 1990
AB 300MG* N89763 001
APR 30, 1990

TIMOLOL MALEATE

TABLET; ORAL
TIMOLOL MALEATE
AB MYLAN 5MG* N72666 001
JUN 08, 1990
AB 10MG* N72667 001
JUN 08, 1990
AB 20MG* N72668 001
JUN 08, 1990
/BX/ /QUANTUM/PHARMICS/ /10MG/ /N72467/001/
/MAY/19,/1989/
/BX/ /20MG/ /N72468/001/
/MAY/19,/1989/
ə QUANTUM PHARMICS 10MG N72467 001
MAY 19, 1989
ə 20MG N72468 001
MAY 19, 1989

TOBRAMYCIN SULFATE

INJECTABLE; INJECTION
TOBRAMYCIN SULFATE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER
ABBOTT EQ 80MG BASE/100ML* N63081 001
JUL 31, 1990
EQ 1.2MG BASE/ML* N63081 003
JUL 31, 1990

TOLAZAMIDE

TABLET; ORAL
TOLAZAMIDE
/AB/ /SUPERPHARM/ /250MG/ /N70763/001/
/JUN/16,/1986/
/AB/ /500MG/ /N70764/001/
/JUN/16,/1986/
ə SUPERPHARM 250MG N70763 001
JUN 16, 1986
ə 500MG N70764 001
JUN 16, 1986

TRAZODONE HYDROCHLORIDE

TABLET; ORAL
DESYREL
AB BRISTOL MYERS 50MG N18207 001
AB 100MG N18207 002
AB 150MG N18207 003
MAR 25, 1985
300MG N18207 004
NOV 07, 1988
/AB/ /MEAD/JOHNSON/ /50MG/ /N18207/001/
/AB/ /100MG/ /N18207/002/
/AB/ /150MG/ /N18207/003/
/MAR/25,/1985/
TRAZODONE HCL
AB CORD 50MG* N72484 001
APR 30, 1990
AB 100MG* N72483 001
APR 30, 1990

TRIAMCINOLONE ACETONIDE

AEROSOL, METERED; INHALATION
AZMACORT
RHONE POULENC RORER 0.25MG/INH N18117 001
APR 23, 1983
/RORER/ /0.25MG/INH/ /N18117/001/
/APR/23,/1983/

CREAM; TOPICAL
/FLUTEX/
/AT/ /SYOSSET/ /0.025%/ /N87430/001/
/NOV/01,/1988/
/AT/ /0.1%/ /N87429/001/
/NOV/01,/1988/
/AT/ /0.5%/ /N87428/001/
/NOV/01,/1988/

TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL

	KENALOG			
/AT/	/SQUIBB/	/0.025%/	/N11601/003/	
/AT/		/0.1%/	/N11601/006/	
AT	WESTWOOD	0.025%	N11601 003	
AT		0.1%	N11601 006	
	TRIATEX			
AT	SYOSSET	0.025%	N87430 001 NOV 01, 1988	
AT		0.1%	N87429 001 NOV 01, 1988	
AT		0.5%	N87428 001 NOV 01, 1988	

OINTMENT; TOPICAL

	KENALOG			
/AT/	/SQUIBB/	/0.025%/	/N11600/003/	
/AT/		/0.1%/	/N11600/001/	
AT	WESTWOOD	0.025%	N11600 003	
AT		0.1%	N11600 001	

TRIAMTERENE

CAPSULE; ORAL

	DYRENIUM			
/SKF/		/50MG/	/N13174/001/	
SKF		50MG	N13174 001	
		/100MG/	/N13174/002/	
		100MG	N13174 002	

TRICHLORMETHIAZIDE

TABLET; ORAL

	TRICHLORMETHIAZIDE			
/BP/	/CHELSEA/	/4MG/	/N85962/001/	
ə CHELSEA		4MG	N85962 001	

TRIENTINE HYDROCHLORIDE

CAPSULE; ORAL

/CUPRID/				
/MSD/		/250MG/	/N19194/001/ NOV/08/1985/	
SYPRINE				
MSD		250MG	N19194 001 NOV 08, 1985	

TRIMEPRAZINE TARTRATE

SYRUP; ORAL

	TRIMEPRAZINE TARTRATE			
/AA/	/BARRE/NAT/	/EQ 2.5MG BASE/5ML/	/N85015/001/	
ə BARRE NAT		EQ 2.5MG BASE/5ML	N85015 001 FEB 18, 1982	

TRIMIPRAMINE MALEATE

CAPSULE; ORAL

	TRIMIPRAMINE MALEATE			
/BX/	/VITARINE/	/EQ/25MG/BASE/	/N71832/001/ SEP/10,/1987/	
/BX/		/EQ/50MG/BASE/	/N71833/001/ SEP/10,/1987/	
/BX/		/EQ/100MG/BASE/	/N71834/001/ SEP/10,/1987/	
ə VITARINE		EQ 25MG BASE	N71832 001 SEP 10, 1987	
ə		EQ 50MG BASE	N71833 001 SEP 10, 1987	
ə		EQ 100MG BASE	N71834 001 SEP 10, 1987	

TRISULFAPYRIMIDINES

SUSPENSION; ORAL

	/TRIPLE SULFA/			
/AA/	/BARRE/NAT/	/500MG/5ML/	/N80280/001/	
ə BARRE NAT		500MG/5ML	N80280 001	

UREA

INJECTABLE; INJECTION

	/STERILE UREA/			
/AP/	/ABBOTT/	/40GM/VIAL/	/N17698/001/	
ə ABBOTT		40GM/VIAL	N17698 001	
	UREAPHIL			
/AP/	/ABBOTT/	/40GM/VIAL/	/N12154/001/	
ABBOTT		40GM/VIAL	N12154 001	

VERAPAMIL HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

	VERELAN			
	ELAN	120MG‡	N19614 001 MAY 29, 1990	
		240MG‡	N19614 002 MAY 29, 1990	

INJECTABLE; INJECTION

	CALAN			
/AP/	/SEARLE/	/2.5MG/ML/	/N19038/001/ MAR/30,/1984/	
ə SEARLE		2.5MG/ML	N19038 001 MAR 30, 1984	
	VERAPAMIL HCL			
/AP/	/LYPHOMED/	/2.5MG/ML/	/N70348/001/ MAY/01,/1986/	
ə LYPHOMED		2.5MG/ML	N70348 001 MAY 01, 1986	

TABLET; ORAL

	VERAPAMIL HCL			
/AB/	/CHELSEA/	/80MG/	/N70421/001/ SEP/17,/1986/	
/AB/		/120MG/	/N70422/001/ SEP/17,/1986/	
BX	CHELSEA	80MG	N70421 001 SEP 17, 1986	
BX		120MG	N70422 001 SEP 17, 1986	

VINBLASTINE SULFATE

INJECTABLE; INJECTION

	VELSAR			
/AP/	/ADRIA/	/10MG/VIAL/	/N89565/001/ AUG/18,/1987/	
AP	BULL	10MG/VIAL	N89565 001 AUG 18, 1987	

VITAMIN A PALMITATE

CAPSULE; ORAL

>DLT>	ALPHALIN			
>DLT>/AA/	/LILLY/	/EQ 50,000 UNITS BASE/	/N80883/001/	
>ADD>	ə LILLY	EQ 50,000 UNITS BASE	N80883 001	
	VITAMIN A			
/AA/	/SQUIBB/	/EQ 50,000 UNITS BASE/	/N80860/001/	
	ə SQUIBB	EQ 50,000 UNITS BASE	N80860 001	

WARFARIN SODIUM

INJECTABLE; INJECTION

	COUMADIN			
	DUPONT	/50MG/VIAL/	/N09218/020/	
		/75MG/VIAL/	/N09218/012/	
	ə DUPONT	50MG/VIAL	N09218 020	
	ə	75MG/VIAL	N09218 012	

TABLET; ORAL

COUMADIN			
DUPONT	1MG‡		N09218 022 MAR 01, 1990

ZIDOVUDINE

INJECTABLE; INJECTION

RETROVIR			
BURROUGHS WELLCOME	10MG/ML‡		N19951 001 FEB 02, 1990

CLOTRIMAZOLE

>ADD>	CREAM; VAGINAL			
>ADD>	GYNE-LOTRIMIN			
>ADD>	SCHERING	1%		N18052 002
>ADD>				NOV 30, 1990
>ADD>	TABLET; VAGINAL			
>ADD>	GYNE-LOTRIMIN			
>ADD>	SCHERING	100MG		N17717 002
>ADD>				NOV 30, 1990

DIPHENHYDRAMINE HYDROCHLORIDE

	SYRUP; ORAL			
	DIPHENHYDRAMINE HCL			
AA	HI TECH	12.5MG/5ML		N72416 001
				SEP 28, 1990

PERMETHRIN

	LOTION; TOPICAL			
	NIX			
	BURROUGHS WELLCOME	1%		N19918 001
				MAY 02, 1990

NO NOVEMBER 1990 APPROVALS

ORPHAN DRUG PRODUCT DESIGNATIONS

SECTION 526 OF THE FEDERAL FOOD, DRUG, AND COSMETIC ACT CONTAINS PROVISIONS WHEREBY FDA MAY DESIGNATE A SPONSOR'S DRUG, ANTIBIOTIC, OR BIOLOGICAL PRODUCT AS A "DESIGNATED ORPHAN DRUG." SECTION 527 OF THE ACT ESTABLISHES A PROCESS WHEREBY A SPONSOR MAY RECEIVE SEVEN YEARS OF EXCLUSIVE APPROVAL STATUS IF THAT SPONSOR IS THE FIRST TO ACHIEVE NEW DRUG, ANTIBIOTIC, OR BIOLOGICAL PRODUCT APPROVAL FOR A DESIGNATED ORPHAN DRUG FOR THE DESIGNATED INDICATION(S). THE EXCLUSIVE APPROVAL MAY BE REVOKED BY WRITTEN CONSENT OF THE SPONSOR OR BY FDA ACTION AFTER FINDING THAT THE SPONSOR HOLDING EXCLUSIVE APPROVAL CANNOT ASSURE THE AVAILABILITY OF SUFFICIENT QUANTITIES OF THE DRUG TO MEET THE NEEDS OF PATIENTS WITH THE DESIGNATED ORPHAN INDICATION(S).

WHEN A PRODUCT IS GRANTED ORPHAN DRUG DESIGNATION, IT WILL APPEAR IN THIS SECTION. ONCE A BIOLOGICAL OR DRUG PRODUCT IS LICENSED/APPROVED FOR MARKETING, IT WILL BE LISTED IN THIS SECTION AND ASTERISKED, AS APPROPRIATE, TO DENOTE MARKETING/EXCLUSIVE APPROVAL STATUS. IN ADDITION, THE EXCLUSIVITY EXPIRATION DATE WILL BE DISPLAYED FOLLOWING THE APPROVED DESIGNATED INDICATION(S).

THE FOLLOWING DRUGS AND BIOLOGICALS HAVE BEEN GRANTED ORPHAN DRUG DESIGNATION PURSUANT TO SECTION 526 OF THE FOOD, DRUG, AND COSMETIC ACT AS AMENDED BY THE ORPHAN DRUG ACT [PUBLIC LAW 97-414].

ORPHAN DRUG PRODUCT DESIGNATIONS

BIOLOGICAL DESIGNATIONS

NAME OF BIOLOGICAL	DESIGNATED USE [EXCLUSIVITY EXPIRATION DATE]	SPONSOR NAME
GENERIC: ANTI-CYTOMEGALOVIRUS MONOCLONAL ANTIBODIES TRADE: NOT ESTABLISHED	PREVENTION OF HUMAN CYTOMEGALOVIRUS INFECTION IN BONE MARROW AND ORGAN TRANSPLANT PATIENTS. TREATMENT OF HUMAN CYTOMEGALOVIRUS INFECTION IN BONE MARROW AND ORGAN TRANSPLANT PATIENTS. PREVENTION OF HUMAN CYTOMEGALOVIRUS INFECTION IN PATIENTS DIAGNOSED WITH AIDS. TREATMENT OF HUMAN CYTOMEGALOVIRUS INFECTION IN PATIENTS DIAGNOSED WITH AIDS.	MEDIMORPHICS
GENERIC: BOTULINUM TOXIN TYPE A TRADE: OCULINUM*/**	TREATMENT OF STRABISMUS ASSOCIATED WITH DYSTONIA IN ADULTS (PATIENTS 12 YEARS OF AGE AND ABOVE). TREATMENT OF BLEPHAROSPASM ASSOCIATED WITH DYSTONIA IN ADULTS (PATIENTS 12 YEARS OF AGE AND ABOVE).*/** [DEC 29, 1996]	ALAN B. SCOTT, M.D.
GENERIC: BOVINE COLOSTRUM TRADE: NOT ESTABLISHED	TREATMENT OF AIDS-RELATED DIARRHEA.	DONALD H. HASTINGS, D.V.M.
GENERIC: COAGULATION FACTOR IX (HUMAN) TRADE: ALPHANINE	FOR USE AS REPLACEMENT THERAPY IN PATIENTS WITH HEMOPHILIA B FOR THE PREVENTION AND CONTROL OF BLEEDING EPISODES, AND DURING SURGERY TO CORRECT DEFECTIVE HEMOSTASIS.	ALPHA THERPTCS
GENERIC: CYTOMEGALOVIRUS IMMUNE GLOBULIN (HUMAN) TRADE: NOT ESTABLISHED*/**	PREVENTION OR ATTENUATION OF PRIMARY CYTOMEGALOVIRUS DISEASE IN IMMUNOSUPPRESSED RECIPIENTS OF ORGAN TRANSPLANTS. [APR 17, 1997]	MASSACHUSETTS PUBLIC HEALTH BIOLOGIC LABS

ORPHAN DRUG PRODUCT DESIGNATIONS

BIOLOGICAL DESIGNATIONS

NAME OF BIOLOGICAL	DESIGNATED USE [EXCLUSIVITY EXPIRATION DATE]	SPONSOR NAME
GENERIC: C1-INHIBITOR TRADE: C1-INHIBITOR (HUMAN) VAPOR HEATED, IMMUNO	PREVENTION OF ACUTE ATTACKS OF ANGIOEDEMA, INCLUDING SHORT-TERM PROPHYLAXIS FOR PATIENTS REQUIRING DENTAL OR OTHER SURGICAL PROCEDURES. TREATMENT OF ACUTE ATTACKS OF ANGIOEDEMA.	IMMUNO CLIN RES
GENERIC: CD4 IMMUNOGLOBULIN G (RECOMBINANT HUMAN) TRADE: NOT ESTABLISHED	TREATMENT OF ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS) RESULTING FROM INFECTION WITH THE HUMAN IMMUNODEFICIENCY VIRUS (HIV-1).	GENETECH
GENERIC: CD-45 MONOCLONAL ANTIBODIES TRADE: NOT ESTABLISHED	PREVENTION OF ACUTE GRAFT REJECTION OF HUMAN ORGAN TRANSPLANTS.	NJC ENTERPRISES
GENERIC: DISACCHARIDE TRIPEPTIDE GLYCEROL DIPALMITOYL (DTP-GDP) TRADE: IMMTHER	TREATMENT OF PULMONARY AND HEPATIC METASTASES IN COLORECTAL ADENOCARCINOMA PATIENTS.	IMMUNOTHERAPEUTICS
GENERIC: GRANULOCYTE-COLONY STIMULATING FACTOR (RECOMBINANT-METHIONYL HUMAN) TRADE: NEUPOGEN	TREATMENT OF MYELODYSPLASTIC SYNDROME. TREATMENT OF NEUTROPENIA ASSOCIATED WITH BONE MARROW TRANSPLANTS. TREATMENT OF PATIENTS WITH SEVERE CHRONIC NEUTROPENIA (ABSOLUTE NEUTROPHIL COUNT LESS THAN 500 PER CUBIC MILLIMETER).	AMGEN
GENERIC: GRANULOCYTE MACROPHAGE-COLONY STIMULATING FACTOR TRADE: NOT ESTABLISHED	TREATMENT OF NEUTROPENIA DUE TO HAIRY CELL LEUKEMIA. TREATMENT OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA TO INCREASE GRANULOCYTE COUNTS.	SCHERING PLOUGH

ORPHAN DRUG PRODUCT DESIGNATIONS

BIOLOGICAL DESIGNATIONS

NAME OF BIOLOGICAL	DESIGNATED USE [EXCLUSIVITY EXPIRATION DATE]	SPONSOR NAME
GENERIC: GROUP B STREPTOCOCCUS IMMUNE GLOBULIN TRADE: NOT ESTABLISHED	TREATMENT OF NEONATES WITH DISSEMINATED GROUP B STREPTOCOCCAL INFECTION.	UNIVAX
GENERIC: [INDIUM 111 MURINE ANTI-CEA MONOCLONAL ANTIBODY TYPE ZCE 025] TRADE: CEAKER	FOR THE DETECTION OF SUSPECTED AND PREVIOUSLY UNIDENTIFIED TUMOR FOCI OF RECURRENT COLORECTAL CARCINOMA.	HYBRITECH
GENERIC: INTERFERON ALPHA-2A (RECOMBINANT) TRADE: ROFERON-A	TREATMENT OF METASTATIC RENAL CELL CARCINOMA IN COMBINATION WITH TECELEUKIN. TREATMENT OF METASTATIC MALIGNANT MELANOMA IN COMBINATION WITH TECELEUKIN. CONCOMITANT ADMINISTRATION WITH FLUOROURACIL FOR THE TREATMENT OF PATIENTS WITH ADVANCED COLORECTAL CANCER.	ROCHE
GENERIC: INTERFERON ALPHA-2B (RECOMBINANT) TRADE: INTRON A	TREATMENT OF PATIENTS WITH CHRONIC DELTA HEPATITIS.	SCHERING PLOUGH
GENERIC: INTERLEUKIN-2 POLYETHYLENE CONJUGATE; RECOMBINANT E. COLI TRADE: NOT ESTABLISHED	TREATMENT OF PRIMARY IMMUNODEFICIENCY DISEASE ASSOCIATED WITH T-CELL DEFECTS.	CETUS
GENERIC: LACTOBIN TRADE: LACTOBIN	TREATMENT OF AIDS ASSOCIATED DIARRHEA UNRESPONSIVE TO INITIAL ANTIDIARRHEAL THERAPY.	ROXANE LABS

ORPHAN DRUG PRODUCT DESIGNATIONS

BIOLOGICAL DESIGNATIONS

NAME OF BIOLOGICAL	DESIGNATED USE [EXCLUSIVITY EXPIRATION DATE]	SPONSOR NAME
GENERIC: LEUKOPOIETIN TRADE: LEUKINE	TREATMENT OF NEUTROPENIA ASSOCIATED WITH BONE MARROW TRANSPLANT, FOR THE PROMOTION OF EARLY ENGRAFTMENT, AND FOR THE TREATMENT OF GRAFT FAILURE AND DELAY OF ENGRAFTMENT.	IMMUNEX
GENERIC: MONOCLONAL ANTIBODIES PM-81 AND AML 2-23 TRADE: NOT ESTABLISHED	FOR EXOGENOUS DEPLETION OF CD14 AND CD15 POSITIVE ACUTE MYELOID LEUKEMIC BONE MARROW CELLS FROM PATIENTS UNDERGOING BONE MARROW TRANSPLANTATION.	MEDAREX
GENERIC: MUCOID EXOPOLYSACCHARIDE PSEUDOMONAS HYPERIMMUNE GLOBULIN TRADE: MEPIG	PREVENTION OF PULMONARY INFECTIONS DUE TO PSEUDOMONAS AERUGINOSA IN PATIENTS WITH CYSTIC FIBROSIS.	UNIVAX BIOLOGICS
GENERIC: ONCORAD OV103 TRADE: NOT ESTABLISHED	TREATMENT OF OVARIAN CARCINOMA.	CYTOGEN
GENERIC: RESPIRATORY SYNCYTIAL VIRUS IMMUNE GLOBULIN (HUMAN) TRADE: HYPERMUNE RSV	PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS LOWER RESPIRATORY INFECTIONS IN INFANTS AND YOUNG CHILDREN AT HIGH RISK OF SEROUS DISEASE. TREATMENT OF RESPIRATORY SYNCYTIAL VIRUS LOWER RESPIRATORY INFECTIONS IN HOSPITALIZED INFANTS AND YOUNG CHILDREN.	MOLECULAR VACCINES
GENERIC: RICIN (BLOCKED) CONJUGATED MURINE MONOCLONAL ANTIBODY (ANTI-MY^9) TO MYELOID CELLS (CD-33) TRADE: NOT ESTABLISHED	FOR USE IN THE EX VIVO TREATMENT OF AUTOLOGOUS BONE MARROW AND SUBSEQUENT REINFUSION IN PATIENTS WITH ACUTE MYELOGENOUS LEUKEMIA.	IMMUNOGEN

ORPHAN DRUG PRODUCT DESIGNATIONS

BIOLOGICAL DESIGNATIONS

NAME OF BIOLOGICAL	DESIGNATED USE [EXCLUSIVITY EXPIRATION DATE]	SPONSOR NAME
GENERIC: TECELEUKIN TRADE: NOT ESTABLISHED	TREATMENT OF METASTATIC MALIGNANT MELANOMA. TREATMENT OF METASTATIC RENAL CELL CARCINOMA. TREATMENT OF METASTATIC MALIGNANT MELANOMA IN COMBINATION WITH ROFERON-A. TREATMENT OF METASTATIC RENAL CELL CARCINOMA IN COMBINATION WITH ROFERON-A (INTERFERON ALPHA-2A, RECOMBINANT/ROCHE).	ROCHE

ORPHAN DRUG PRODUCT DESIGNATIONS

DRUG DESIGNATIONS

NAME OF DRUG	DESIGNATED USE [EXCLUSIVITY EXPIRATION DATE]	SPONSOR NAME
GENERIC: ALL-TRANS RETINOIC ACID TRADE: NOT ESTABLISHED	TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA.	ROCHE
GENERIC: ALPHA-GALACTOSIDASE A TRADE: FABRASE	TREATMENT OF FABRY'S DISEASE.	ROBERT J. DESNICK, M.D., PH.D. MOUNT SINAI SCHOOL OF MEDICINE
GENERIC: AMILORIDE HCL SOLUTION FOR INHALATION TRADE: NOT ESTABLISHED	TREATMENT OF CYSTIC FIBROSIS.	GLAXO
GENERIC: BMY-45622 TRADE: NOT ESTABLISHED	TREATMENT OF OVARIAN CANCER.	BRISTOL SQUIBB
GENERIC: CALCITONIN SALMON NASAL SPRAY TRADE: MIACALCIN	TREATMENT OF SYMPTOMATIC PAGAT'S DISEASE OF BONE (OSTEITIS DEFORMANS).	SANDOZ
GENERIC: CALCIUM CARBONATE TRADE: R & D CALCIUM CARBONATE/600	TREATMENT OF HYPERPHOSPHATEMIA IN PATIENTS WITH END STAGE RENAL DISEASE (ESRD).	R AND D LABS
GENERIC: CALCIUM GLUCONATE GEL 2.5% TRADE: NOT ESTABLISHED	EMERGENCY TOPICAL TREATMENT OF HYDROGEN FLUORIDE (HYDROFLUORIC ACID) BURNS.	PADDOCK LABS
GENERIC: COLFOSCERIL PALMITATE TRADE: EXOSURF NEONATAL*/**	PREVENTION OF HYALINE MEMBRANE DISEASE (HMD), ALSO KNOWN AS RESPIRATORY DISTRESS SYNDROME (RDS), IN INFANTS BORN AT 32 WEEKS GESTATION OR LESS.*/** [AUG 02, 1997] TREATMENT OF ESTABLISHED HMD AT ALL GESTATIONAL AGES.*/** [AUG 02, 1997]	BURROUGHS WELLC

ORPHAN DRUG PRODUCT DESIGNATIONS

DRUG DESIGNATIONS

NAME OF DRUG	DESIGNATED USE [EXCLUSIVITY EXPIRATION DATE]	SPONSOR NAME
GENERIC: CROMOLYN SODIUM TRADE: GASTROCROM*/**	MASTOCYTOSIS. [DEC 22, 1996]	FISONS
GENERIC: DEHYDREX TRADE: NOT ESTABLISHED	TREATMENT OF RECURRENT CORNEAL EROSION UNRESPONSIVE TO CONVENTIONAL THERAPY.	HOLLES LABS
GENERIC: DEXTRAN SULFATE (INHALED, AEROSOLIZED) TRADE: UENDEX	ADJUNCT TO THE TREATMENT OF CYSTIC FIBROSIS.	THOMAS P. KENNEDY, M.D. J. HOIDAL, M.D. DUKE UNIVERSITY MEDICAL CENTER
GENERIC: DISODIUM CLODRONATE TETRAHYDRATE TRADE: BONEFOS	TREATMENT OF INCREASED BONE RESORPTION DUE TO MALIGNANCY.	LEIRAS PHARMS
GENERIC: DYNAMINE TRADE: NOT ESTABLISHED	TREATMENT OF LAMBERT-EATON MYASTHENIC SYNDROME.	MAYO CLINIC AND FOUNDATION
GENERIC: FLUOROURACIL	CONCOMITANT ADMINISTRATION WITH ROFERON-A FOR THE TREATMENT OF PATIENTS WITH ADVANCED COLORECTAL CANCER.	ROCHE
GENERIC: GENTAMICIN LIPOSOME INJECTION TRADE: NOT ESTABLISHED	TREATMENT OF DISSEMINATED MYCOBACTERIUM AVIUM-INTRACELLULARE INFECTION.	LIPOSOME
GENERIC: GONADORELIN ACETATE TRADE: LUTREPULSE*/**	TREATMENT OF PRIMARY HYPOTHALAMIC AMENORRHEA. [OCT 10, 1996]	RW JOHNSON

ORPHAN DRUG PRODUCT DESIGNATIONS

DRUG DESIGNATIONS

NAME OF DRUG	DESIGNATED USE [EXCLUSIVITY EXPIRATION DATE]	SPONSOR NAME
GENERIC: GOSSYPOL TRADE: NOT ESTABLISHED	TREATMENT OF CANCER OF THE ADRENAL CORTEX.	MARCUS M. REIDENBERG, M.D. CORNELL UNIVERSITY MEDICAL COLLEGE
GENERIC: HYDROXYUREA TRADE: HYDREA	TREATMENT OF SICKLE CELL ANEMIA AS SHOWN BY THE PRESENCE OF HEMOGLOBIN S.	BRISTOL SQUIBB
GENERIC: IDARUBICIN HYDROCHLORIDE TRADE: IDAMYCIN*/**	TREATMENT OF ACUTE MYELOGENOUS LEUKEMIA (AML), ALSO REFERRED TO AS ACUTE NONLYMPHOCYTIC LEUKEMIA (ANLL). [SEP 27, 1990]	ADRIA LABS
GENERIC: ILOPROST TRADE: NOT ESTABLISHED	TREATMENT OF HEPARIN-ASSOCIATED THROMBOCYTOPENIA.	BERLEX LABS
GENERIC: L-BACLOFEN TRADE: NOT ESTABLISHED	TREATMENT OF TRIGEMINAL NEURALGIA.	GERHARD H. FROMM, M.D. UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE
GENERIC: LEUPEPTIN TRADE: NOT ESTABLISHED	ADJUNCT TO MICROSURGICAL PERIPHERAL NERVE REPAIR.	LAWRENCE C. HURST, M.D. STATE UNIVERSITY OF NEW YORK
GENERIC: LIOTHYRONINE INJECTION TRADE: NOT ESTABLISHED	TREATMENT OF MYXEDEMA COMA/PRE-COMA.	SMITHKLINE BEECHAM
GENERIC: MAFENIDE ACETATE SOLUTION TRADE: SULFAMYLON	FOR USE IN THE PREVENTION OF GRAFT LOSS OF MESHED AUTOGRAFTS ON EXCISED BURN WOUNDS.	STERLING DRUG

ORPHAN DRUG PRODUCT DESIGNATIONS

DRUG DESIGNATIONS

NAME OF DRUG	DESIGNATED USE [EXCLUSIVITY EXPIRATION DATE]	SPONSOR NAME
GENERIC: MEFLOQUINE HCL TRADE: LARIAM*/**	TREATMENT OF ACUTE MALARIA DUE TO PLASMODIUM FALCIPARUM AND PLASMODIUM VIVAX.*/** [MAY 02, 1996] PROPHYLAXIS OF PLASMODIUM FALCIPARUM MALARIA WHICH IS RESISTANT TO OTHER AVAILABLE DRUGS.*/** [MAY 02, 1996]	ROCHE
GENERIC: METHOTREXATE USP WITH LAUROCAPRAM TRADE: NOT ESTABLISHED	TOPICAL TREATMENT OF MYCOSIS FUNGOIDES.	WHITBY RES
GENERIC: MICROBUBBLE CONTRAST AGENT TRADE: FILMIX (NEUROSONOGRAPHIC CONTRAST AGENT)	INTRAOPERATIVE AID IN THE IDENTIFICATION AND LOCALIZATION OF INTRACRANIAL TUMORS.	CAV-CON
GENERIC: MORPHINE SULFATE CONCENTRATE TRADE: INFUMORPH	FOR USE IN MICROINFUSION DEVICES FOR INTRASPINAL ADMINISTRATION IN THE TREATMENT OF INTRACTABLE CHRONIC PAIN.	ELKINS SINN
GENERIC: N-ACETYL PROCAINAMIDE TRADE: NAPA	TO LOWER THE DEFIBRILLATION ENERGY REQUIREMENT SUFFICIENTLY TO ALLOW AUTOMATIC IMPLANTABLE CARDIOVERTER DEFIBRILLATOR (AICD) THERAPY IN THOSE PATIENTS WHO COULD OTHERWISE NOT USE THE DEVICE.	MEDCO RES
GENERIC: OXANDROLONE TRADE: NOT ESTABLISHED	TREATMENT OF CONSTITUTIONAL DELAY OF GROWTH AND PUBERTY. TREATMENT OF SHORT STATURE ASSOCIATED WITH TURNER'S SYNDROME.	GYNEX

ORPHAN DRUG PRODUCT DESIGNATIONS

DRUG DESIGNATIONS

NAME OF DRUG	DESIGNATED USE [EXCLUSIVITY EXPIRATION DATE]	SPONSOR NAME
GENERIC: PEGADEMASE BOVINE TRADE: ADAGEN*/**	USE AS ENZYME REPLACEMENT THERAPY FOR ADENOSINE DEAMINASE (ADA) DEFICIENCY IN PATIENTS WITH SEVERE COMBINED IMMUNODEFICIENCY (SCID) WHO ARE NOT SUITABLE CANDIDATES FOR (OR WHO HAVE FAILED) BONE MARROW TRANSPLANTATION. [MAR 21, 1997]	ENZON
GENERIC: PILOCARPINE HCL TRADE: NOT ESTABLISHED	TREATMENT OF XEROSTOMIA INDUCED BY RADIATION THERAPY FOR HEAD AND NECK CANCER.	MGI PHARMA
GENERIC: POLOXAMER 188 TRADE: RHEOTHRX COPOLYMER	TREATMENT OF SEVERE BURNS REQUIRING HOSPITALIZATION.	CYTRX
GENERIC: PR-122 (REDOX-PHENYTOIN) TRADE: NOT ESTABLISHED	FOR THE EMERGENCY RESCUE TREATMENT OF STATUS EPILEPTICUS, GRAND MAL TYPE.	PHARMATEC
GENERIC: PR-225 (REDOX ACYCLOVIR) TRADE: NOT ESTABLISHED	TREATMENT OF HERPES SIMPLEX ENCEPHALITIS IN INDIVIDUALS AFFLICTED WITH AIDS.	PHARMATEC
GENERIC: PR-239 (REDOX PENICILLIN G) TRADE: NOT ESTABLISHED	TREATMENT OF AIDS ASSOCIATED NEUROSYPHILIS.	PHARMATEC
GENERIC: PR-320 (MOLECUSOL-CARBAMAZEPINE) TRADE: NOT ESTABLISHED	FOR THE EMERGENCY RESCUE TREATMENT OF STATUS EPILEPTICUS, GRAND MAL TYPE.	PHARMATEC
GENERIC: RHEOTHRX TRADE: NOT ESTABLISHED	TREATMENT OF SEVERE BURNS IN HOSPITALIZED PATIENTS.	CYTRX

ORPHAN DRUG PRODUCT DESIGNATIONS

DRUG DESIGNATIONS

NAME OF DRUG	DESIGNATED USE [EXCLUSIVITY EXPIRATION DATE]	SPONSOR NAME
GENERIC: SERMORELIN ACETATE TRADE: GEREF	AS AN ADJUNCT TO GONADOTROPIN THERAPY IN THE INDUCTION OF OVULATION IN WOMEN WITH ANOVULATORY OR OLIGO-OVULATORY INFERTILITY WHO FAIL TO OVULATE IN RESPONSE TO ADEQUATE TREATMENT WITH CLOMIPHENE CITRATE ALONE AND GONADOTROPIN THERAPY ALONE.	SERONO LABS
GENERIC: SHORT CHAIN FATTY ACID SOLUTION TRADE: NOT ESTABLISHED	TREATMENT OF THE ACTIVE PHASE OF ULCERATIVE COLITIS WITH INVOLVEMENT RESTRICTED TO THE LEFT SIDE OF THE COLON.	RICHARD I. BREUER EVANSTON HOSP
GENERIC: SK&F 110679 TRADE: NOT ESTABLISHED	LONG TERM TREATMENT OF CHILDREN WHO HAVE GROWTH FAILURE DUE TO A LACK OF ADEQUATE ENDOGENOUS GROWTH HORMONE SECRETION.	SK&F LABS
GENERIC: SODIUM DICHLOROACETATE TRADE: NOT ESTABLISHED	TREATMENT OF CONGENITAL LACTIC ACIDOSIS. TREATMENT OF HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA.	PETER STACPOOLE, M.D., PH.D. UNIVERSITY OF FLORIDA
GENERIC: SOMATROPIN TRADE: HUMATROPE	TREATMENT OF SHORT STATURE ASSOCIATED WITH TURNER'S SYNDROME.	LILLY
GENERIC: SUCRALFATE TRADE: NOT ESTABLISHED	TREATMENT OF ORAL COMPLICATIONS OF CHEMOTHERAPY IN BONE MARROW TRANSPLANT RECIPIENTS.	NASKA PHARMA
GENERIC: SULFAPYRIDINE TRADE: NOT ESTABLISHED	TREATMENT OF DERMATITIS HERPETIFORMIS.	JACOBUS PHARM

ORPHAN DRUG PRODUCT DESIGNATIONS

DRUG DESIGNATIONS

NAME OF DRUG	DESIGNATED USE [EXCLUSIVITY EXPIRATION DATE]	SPONSOR NAME
GENERIC: THALIDOMIDE TRADE: NOT ESTABLISHED	TREATMENT OF GRAFT VERSUS HOST DISEASE (GVHD) IN PATIENTS RECEIVING BONE MARROW TRANSPLANTATION (BMT). PREVENTION OF GVHD IN PATIENTS RECEIVING BMT.	ANDRULIS RES
GENERIC: TRIPTORELIN PAMOATE TRADE: DECAPEPTYL INJECTION	FOR USE IN THE PALLIATIVE TREATMENT OF ADVANCED OVARIAN CARCINOMA OF EPITHELIAL ORIGIN.	ORGANON
GENERIC: 2-CHLORODEOXYADENOSINE TRADE: NOT ESTABLISHED	TREATMENT OF HAIRY CELL LEUKEMIA.	RW JOHNSON
GENERIC: 2-CHLORO-2'-DEOXYADENOSINE TRADE: NOT ESTABLISHED	TREATMENT OF ACUTE MYELOID LEUKEMIA.	ST JUDE CHILDRENS
GENERIC: 2,3-DIMERCAPTOSUCCINIC ACID TRADE: CHEMET	PREVENTION OF CYSTINE KIDNEY STONE FORMATION IN PATIENTS WITH HOMOZYGOUS CYSTINURIA WHO ARE PRONE TO STONE DEVELOPMENT.	MCNEIL CONSUMER
GENERIC: 566C80 TRADE: NOT ESTABLISHED	TREATMENT OF AIDS ASSOCIATED PNEUMOCYSTIS CARINII PNEUMONIA (PCP).	BURROUGHS WELLC

DRUG PRODUCTS WHICH MUST DEMONSTRATE IN VIVO BIOAVAILABILITY ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION

NO NOVEMBER 1990 ADDITIONS

BIOPHARMACEUTIC GUIDANCE AVAILABILITY

THE FOLLOWING IS A LIST OF GUIDANCES AVAILABLE FOR IN VIVO BIOEQUIVALENCE STUDIES AND IN VITRO DISSOLUTION TESTING AVAILABLE FROM THE DIVISION OF BIOEQUIVALENCE, HFD-650, ROOM 17B-06, 5600 FISHERS LANE, ROCKVILLE, MD 20857. COMMENTS AND SUGGESTIONS CONCERNING THESE GUIDANCES ARE ENCOURAGED AND SHOULD BE SENT TO THE DIVISION OF BIOEQUIVALENCE.

REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 10TH EDITION FOR A FULL LISTING OF BIOPHARMACEUTIC GUIDANCE AVAILABILITY DATA. ONLY NEW DATA WILL BE ADDED TO THE CUMULATIVE SUPPLEMENT.

DRUG NAME (DOSAGE FORM)	DATE	REVISED DATE
THEOPHYLLINE (CAPSULE AND TABLET)	SEP 07, 1984	
THEOPHYLLINE (CAPSULE, EXTENDED RELEASE AND TABLET, EXTENDED RELEASE)	SEP 07, 1984	
ONCE A DAY DOSING/SINGLE DOSE STUDY		
TWICE A DAY DOSING/SINGLE DOSE STUDY		
ONCE A DAY DOSING/MULTIPLE DOSE STUDY		
TWICE A DAY DOSING/MULTIPLE DOSE STUDY		

ANDA SUITABILITY PETITIONS

THE FOLLOWING ARE TWO LISTS OF PETITIONS FILED UNDER SECTION 505(j)(2)(C) OF THE ACT WHERE THE AGENCY HAS DETERMINED THAT THE REFERENCED PRODUCT: (1) IS SUITABLE FOR SUBMISSION AS AN ANDA (PETITIONS APPROVED) OR (2) IS NOT SUITABLE FOR SUBMISSION AS AN ANDA (PETITIONS DENIED). THE DETERMINATION THAT AN ANDA WILL BE APPROVED IS NOT MADE UNTIL THE ANDA ITSELF IS SUBMITTED AND REVIEWED BY THE AGENCY. A COPY OF EACH PETITION IS LISTED BY DOCKET NUMBER ON PUBLIC DISPLAY IN FDA'S DOCKETS MANAGEMENT BRANCH, HFA-305, ROOM 4-62, 5600 FISHERS LANE, ROCKVILLE, MD 20857.

REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 10TH EDITION FOR A FULL LISTING OF ANDA SUITABILITY PETITIONS DATA. ONLY NEW DATA WILL BE ADDED TO THE CUMULATIVE SUPPLEMENT.

PETITIONS APPROVED

DRUG NAME DOSAGE FORM; ROUTE	STRENGTH (CONTAINER SIZE)	DOCKET NUMBER	PETITIONER	REASON FOR PETITION	STATUS
ALBUTEROL SULFATE SOLUTION; ORAL	2MG/5ML	89 P-0447/CP	BIOCRAFT LABS	NEW DOSAGE FORM	APPROVED MAR 15, 1990
ASPIRIN; HYDROCODONE BITARTRATE TABLET; ORAL	650MG 7.5MG	90 P-0050/CP	MASON PHARMS	NEW STRENGTH	APPROVED JUN 01, 1990
CHLORZOXAZONE CAPSULE; ORAL	250MG	90 P-0084/ CP0001	MIKART	NEW DOSAGE FORM	APPROVED MAY 24, 1990
HYDROCORTISONE SOLUTION; TOPICAL	2.5%	89 P-0175/CP	GENDERM	NEW STRENGTH	APPROVED JAN 11, 1990
HYDROCORTISONE ACETATE CREAM; TOPICAL	2.5%	90 P-0049/CP	FERNDALE LABS	NEW STRENGTH	APPROVED JUN 22, 1990
HYDROCORTISONE ACETATE LOTION; TOPICAL	1%	90 P-0049/CP	FERNDALE LABS	NEW DOSAGE FORM	APPROVED JUN 22, 1990

ANDA SUITABILITY PETITIONS

PETITIONS APPROVED

DRUG NAME DOSAGE FORM; ROUTE	STRENGTH (CONTAINER SIZE)	DOCKET NUMBER	PETITIONER	REASON FOR PETITION	STATUS
HYDROCORTISONE ACETATE LOTION; TOPICAL	2.5%	90 P-0049/CP	FERNDALE LABS	NEW DOSAGE FORM	APPROVED JUN 22, 1990
ISOSORBIDE DINITRATE TABLET, EXTENDED RELEASE; ORAL	60MG	89 P-0485/CP	ADRIA LABS	NEW STRENGTH	APPROVED JUN 01, 1990
NITROGLYCERIN IN DEXTROSE 5% INJECTABLE; INJECTION	0.05MG/ML (500ML/CONTAINER)	89 P-0422/CP	LYPHOMED	NEW STRENGTH	APPROVED APR 20, 1990
NITROGLYCERIN IN DEXTROSE 5% INJECTABLE; INJECTION	0.2MG/ML (500ML/CONTAINER)	89 P-0422/CP	LYPHOMED	NEW STRENGTH	APPROVED APR 20, 1990
PENTAMIDINE ISETHIONATE INJECTABLE; INJECTION	100MG/ML (3ML/VIAL)	89 P-0435/CP	ASTRA PHARM PRODS	NEW DOSAGE FORM	APPROVED JAN 18, 1990
THEOPHYLLINE TABLET; ORAL	150MG	89 P-0499/CP	SCI CONSULTING	NEW STRENGTH	APPROVED MAY 03, 1990
TOLMETIN SODIUM TABLET; ORAL	EQ 400MG BASE	90 P-0011/CP	QUANTUM PHARMCS	NEW STRENGTH	APPROVED MAY 03, 1990
VERAPAMIL HYDROCHLORIDE TABLET, EXTENDED RELEASE; ORAL	120MG	89 P-0220/CP	LEDERLE LABS	NEW STRENGTH	APPROVED JAN 11, 1990

ANDA SUITABILITY PETITIONS

PETITIONS DENIED

DRUG NAME DOSAGE FORM; ROUTE	STRENGTH (CONTAINER SIZE)	DOCKET NUMBER	PETITIONER	REASON FOR PETITION	STATUS
CLONIDINE HYDROCHLORIDE CAPSULE, EXTENDED RELEASE; ORAL	0.2MG	88 P-0365/CP	BOEHR INGEL	NEW DOSAGE FORM	DENIED JAN 11, 1990

EXCLUSIVITY TERMS

DUE TO SPACE LIMITATIONS IN THE EXCLUSIVITY COLUMN, ABBREVIATIONS AND REFERENCES HAVE BEEN DEVELOPED. REFER BACK TO THE APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 10TH EDITION FOR A FULL LISTING OF EXCLUSIVITY TERMS (ABBREVIATIONS, NEW DOSING SCHEUDLE, NEW INDICATIONS AND PATENT USE CODES). ONLY NEW CODES WILL BE ADDED TO THE CUMULATIVE SUPPLEMENT.

REFERENCES
NEW INDICATION

I-41	MIGRAINE HEADACHE PROPHYLAXIS
I-42	HERPES ZOSTER
I-43	HERPES SIMPLEX ENCEPHALITIS
I-44	MAINTENANCE THERAPY IN HEALED DUODENAL ULCER PATIENTS AT DOSE OF 1 GRAM TWICE DAILY
I-45	ACUTE TREATMENT OF VARICELLA ZOSTER VIRUS
I-46	USE IN PEDIATRIC COMPUTED TOMOGRAPHIC HEAD AND BODY IMAGING
I-47	TREATMENT OF PEDIATRIC PATIENTS WITH SYMPTOMATIC HUMAN IMMUNODEFICIENCY VIRUS (HIV) DISEASE
I-48	PEDIATRIC ANGIOCARDIOGRAPHY
I-49	TREATMENT OF TRAVELERS' DIARRHEA DUE TO SUSCEPTIBLE STRAINS OF ENTEROTOXIGENIC ESCHERICHIA COLI
I-50	FOR USE IN WOMEN WITH AXILLARY NODE-NEGATIVE BREAST CANCER
I-51	TREATMENT OF PRIMARY DYSMENORRHEA AND FOR THE TREATMENT OF IDIOPATHIC HEAVY MENSTRUAL BLOOD LOSS
I-52	PEDIATRIC EXCRETORY UROGRAPHY
I-53	TREATMENT OF PANIC DISORDER, WITH OR WITHOUT AGORAPHOBIA

REFERENCES
PATENT USE CODE

U-42	ADJUVANT TREATMENT IN COMBINATION WITH FLUOROURACIL AFTER SURGICAL RESECTION IN PATIENTS WITH DUKES' STAGE C COLON CANCER
U-43	MANAGEMENT OF CHRONIC PAIN IN PATIENTS REQUIRING OPIOID ANALGESIA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	18828 001	ACYCLOVIR; ZOVIRAX				I-45	APR 20, 1993
	19909 001	ACYCLOVIR; ZOVIRAX				I-45	APR 26, 1993
	18603 001	ACYCLOVIR SODIUM; ZOVIRAX				I-43	FEB 09, 1993
						I-42	FEB 09, 1993
>ADD>	18276 001	ALPRAZOLAM; XANAX	3980789	SEP 14, 1993		I-53	NOV 06, 1993
>ADD>	18276 002	ALPRAZOLAM; XANAX	3980789	SEP 14, 1993		I-53	NOV 06, 1993
>ADD>	18276 003	ALPRAZOLAM; XANAX	3980789	SEP 14, 1993		I-53	NOV 06, 1993
>ADD>	18276 004	ALPRAZOLAM; XANAX	3987052	OCT 19, 1993		I-53	NOV 06, 1993
	19155 001	AMMONIUM LACTATE; LAC-HYDRIN	4105783	OCT 26, 1995			
>ADD>	19429 003	ASPIRIN; FIORINAL W/CODEINE NO 3				NC	OCT 26, 1993
	18240 004	ATENOLOL; TENORMIN	3934032	JAN 20, 1993	U-3		
			3836671	SEP 17, 1991	U-39	I-39	SEP 13, 1992
			3836671	SEP 17, 1991	U-8		
	72303 001	ATENOLOL; ATENOLOL	3934032	JAN 20, 1993	U-3	I-39	SEP 13, 1992
			3836671	SEP 17, 1991	U-39		
			3836671	SEP 17, 1991	U-8		
	72304 001	ATENOLOL; ATENOLOL	3934032	JAN 20, 1993	U-3	I-39	SEP 13, 1992
			3836671	SEP 17, 1991	U-39		
			3836671	SEP 17, 1991	U-8		
	19845 001	BETAXOLOL HYDROCHLORIDE; BETOPTIC S	4311708	JAN 19, 1999		NDF	DEC 29, 1992
	19880 001	CARBOPLATIN; PARAPLATIN	4140707	AUG 25, 1998			
	19880 002	CARBOPLATIN; PARAPLATIN	4140707	AUG 25, 1998			
	19880 003	CARBOPLATIN; PARAPLATIN	4140707	AUG 25, 1998			
	19972 001	CARTEOLOL HYDROCHLORIDE; OPTIPRESS	4309432	JAN 05, 1999		NDF	MAY 23, 1993
			3910924	OCT 07, 1994		NCE	DEC 28, 1993
	19481 001	CITRIC ACID; RENACIDIN				ODE	OCT 02, 1997
	19966 001	CLOBETASOL PROPIONATE; TEMOVATE	3721687	MAR 20, 1992		NP	FEB 22, 1993
						NCE	DEC 27, 1990
	20044 001	COLFOSCERIL PALMITATE; EXOSURF NEONATAL	4826821	MAY 02, 2006		ODE	AUG 02, 1997
			4312860	JAN 26, 1999		NCE	AUG 02, 1995
>ADD>	19668 001	DOXAZOSIN MESYLATE; CARDURA				NCE	NOV 02, 1995
>ADD>	19668 002	DOXAZOSIN MESYLATE; CARDURA				NCE	NOV 02, 1995
>ADD>	19668 003	DOXAZOSIN MESYLATE; CARDURA				NCE	NOV 02, 1995
>ADD>	19668 004	DOXAZOSIN MESYLATE; CARDURA				NCE	NOV 02, 1995
>ADD>	19879 002	EFLORNITHINE HYDROCHLORIDE; ORNIDYL	4413141	NOV 01, 2000		ODE	NOV 28, 1997
>ADD>			4339151	AUG 16, 2000		NCE	NOV 28, 1995
>ADD>	19653 001	ETHINYL ESTRADIOL; ORTHO CYCLEN-21	4027019	MAY 31, 1996		NC	DEC 29, 1992
>OLT>	19653 001	ETHINYL ESTRADIOL; ORTHO CYCLEN-21	4027019	MAY 31, 1996		NC	DEC 29, 1992
>ADD>	19653 002	ETHINYL ESTRADIOL; ORTHO CYCLEN-28	4027019	MAY 31, 1996		NC	DEC 29, 1992
>OLT>	19653 002	ETHINYL ESTRADIOL; ORTHO CYCLEN-28	4027019	MAY 31, 1996		NC	DEC 29, 1992

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	19813 001	FENTANYL; DURAGESIC	4588580	MAY 13, 2003	U-43		
			4144317	SEP 09, 1992			
			4060084	JUN 28, 1994	U-43	NDF	AUG 07, 1993
	19813 002	FENTANYL; DURAGESIC	4588580	MAY 13, 2003	U-43		
			4144317	SEP 09, 1992			
			4060084	JUN 28, 1994	U-43		
						NDF	AUG 07, 1993
	19813 003	FENTANYL; DURAGESIC	4588580	MAY 13, 2003	U-43		
			4144317	SEP 09, 1992			
	19813 003	FENTANYL; DURAGESIC	4060084	JUN 28, 1994	U-43		
						NDF	AUG 07, 1993
	19813 004	FENTANYL; DURAGESIC	4588580	MAY 13, 2003	U-43		
			4144317	SEP 09, 1992			
			4060084	JUN 28, 1994	U-43		
						NDF	AUG 07, 1993
	19949 001	FLUCONAZOLE; DIFLUCAN	4416682	NOV 22, 2000			
			4404216	SEP 13, 2000		NCE	JAN 29, 1995
	19949 002	FLUCONAZOLE; DIFLUCAN	4416682	NOV 22, 2000			
			4404216	SEP 13, 2000		NCE	JAN 29, 1995
	19949 003	FLUCONAZOLE; DIFLUCAN	4416682	NOV 22, 2000			
			4404216	SEP 13, 2000		NCE	JAN 29, 1995
	19950 001	FLUCONAZOLE; DIFLUCAN	4416682	NOV 22, 2000			
			4404216	SEP 13, 2000		NCE	JAN 29, 1995
						NDF	AUG 27, 1993
	20001 001	FLUOCINOLONE ACETONIDE; FS SHAMPOO	4329364	MAY 11, 2001	U-23		
	18554 001	FLUTAMIDE; EULEXIN	4963344	MAR 03, 2004		I-38	AUG 10, 1992
	19596 001	GADOPENTETATE DIMEGLUMINE; MAGNEVIST	4957939	MAR 03, 2004		I-31	APR 28, 1992
>ADD>	19661 001	GANCICLOVIR SODIUM; CYTOVENE	4355032	MAR 16, 2003	U-33	NCE	JUN 23, 1994
>DLT>	19661 001	GANCICLOVIR SODIUM; CYTOVENE	4355032	OCT 19, 1999	U-33	NCE	JUN 23, 1994
	19032 001	GUANFACINE HYDROCHLORIDE; TENEX	3632645	OCT 26, 1990		NCE	OCT 27, 1991
	19032 002	GUANFACINE HYDROCHLORIDE; TENEX	3632645	OCT 26, 1990		NCE	OCT 27, 1991
	19032 003	GUANFACINE HYDROCHLORIDE; TENEX	3632645	OCT 26, 1990		NCE	OCT 27, 1991
	17556 001	HALCINONIDE; HALOG	3892857	JUL 01, 1992			
	17818 001	HALCINONIDE; HALOG	3892857	JUL 01, 1992			
	17824 001	HALCINONIDE; HALOG	3892856	JUL 01, 1992			
	18234 001	HALCINONIDE; HALOG-E	4048310	SEP 13, 1994			
	50661 001	IDARUBICIN HYDROCHLORIDE; IDAMYCIN				ODE	SEP 27, 1997
	50661 002	IDARUBICIN HYDROCHLORIDE; IDAMYCIN				ODE	SEP 27, 1997
	19693 001	INDECAINIDE HYDROCHLORIDE; DECABID	4382093	MAY 03, 2000			
	19693 002	INDECAINIDE HYDROCHLORIDE; DECABID	4382093	MAY 03, 2000			
	19693 003	INDECAINIDE HYDROCHLORIDE; DECABID	4382093	MAY 03, 2000			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	18956 002	IOHEXOL; OMNIPAQUE 240	4021481	MAY 03, 1994			
	18735 002	IOPAMIDOL; ISOVUE-300				I-46	MAY 30, 1993
						I-52	SEP 21, 1993
	18735 003	IOPAMIDOL; ISOVUE-370				I-48	OCT 04, 1992
	19580 001	IOTROLAN; OSMOVIST	4239747	DEC 16, 1999		NCE	DEC 07, 1994
	19580 002	IOTROLAN; OSMOVIST	4239747	DEC 16, 1999		NCE	DEC 07, 1994
	19927 001	KETOCONAZOLE; NIZORAL	4335125	JUN 15, 1999		NDF	AUG 31, 1993
	20011 001	LEUPROLIDE ACETATE; LUPRON DEPOT	4005063	JAN 25, 1996		NP	OCT 22, 1993
	20035 001	LEVAMISOLE HYDROCHLORIDE; ERGAMISOL	4584305	APR 22, 2003	U-42	NCE	JUN 18, 1995
	18006 001	MECLOFENAMATE SODIUM; MECLOMEN				I-51	JUL 23, 1993
	18006 002	MECLOFENAMATE SODIUM; MECLOMEN				I-51	JUL 23, 1993
	19591 001	MEFLOQUINE HYDROCHLORIDE; LARIAM				ODE	MAY 02, 1996
	19907 001	METIPRANOLOL HYDROCHLORIDE; OPTIPRANOLOL				NCE	DEC 29, 1994
	19786 001	METOPROLOL FUMARATE; LOPRESSOR	3916899	NOV 04, 1992			
			3845770	NOV 05, 1991			
	19786 002	METOPROLOL FUMARATE; LOPRESSOR	3916899	NOV 04, 1992			
			3845770	NOV 05, 1991			
	19786 003	METOPROLOL FUMARATE; LOPRESSOR	4892739	JAN 09, 2007			
			3916899	NOV 04, 1992			
			3845770	NOV 05, 1991			
	19786 004	METOPROLOL FUMARATE; LOPRESSOR	4892739	JAN 09, 2007			
			3916899	NOV 04, 1992			
			3845770	NOV 05, 1991			
	19753 001	MORICIZINE HYDROCHLORIDE; ETHMOZINE	3864487	FEB 04, 1992			
			3740395	JUN 19, 1990		NCE	JUN 19, 1995
	19753 002	MORICIZINE HYDROCHLORIDE; ETHMOZINE	3864487	FEB 04, 1992			
			3740395	JUN 19, 1990		NCE	JUN 19, 1995
	19753 003	MORICIZINE HYDROCHLORIDE; ETHMOZINE	3864487	FEB 04, 1992			
			3740395	JUN 19, 1990		NCE	JUN 19, 1995
	19886 001	NAFARELIN ACETATE; SYNAREL	4234571	NOV 18, 1997		NCE	FEB 13, 1995
	19356 001	NAFTIFINE HYDROCHLORIDE; NAFTIN	4282251	AUG 04, 1998		NCE	MAR 01, 1993
						NDF	JUN 18, 1993
	19599 001	NAFTIFINE HYDROCHLORIDE; NAFTIN				D-1	JUL 05, 1993
	72409 001	NIFEDIPINE; NIFEDIPINE				PC	MAR 02, 1991
	19715 001	OLSALAZINE SODIUM; DIPENTUM				NCE	JUL 31, 1995
>ADD>	19810 001	OMEPRAZOLE; PRILOSEC	4255431	MAR 10, 2002			
>DLT>	19810 001	OMEPRAZOLE; PRILOSEC	4255431	MAR 10, 2000			

PRESCRIPTION AND OTC DRUG PRODUCT
PATENT AND EXCLUSIVITY DATA

	APPL/PROD NUMBER	INGREDIENT NAME; TRADE NAME	PATENT NUMBER	PATENT EXPIRES	USE CODE	EXCLUS CODE	EXCLUS EXPIRES
	19818 001	PEGADEMASE BOVINE; ADAGEN	4179337	DEC 18, 1996		ODE	MAR 21, 1997
						NCE	MAR 21, 1995
	19918 001	PERMETHRIN; NIX	4024163	MAY 17, 1996		NCE	MAR 31, 1991
	19638 001	PIPECURONIUM BROMIDE; ARDUAN				NCE	JUN 26, 1995
	87361 001	PROCAINAMIDE HYDROCHLORIDE; PRONESTYL-SR	4252786	FEB 24, 1998			
>ADD>	19627 001	PROPOFOL; DIPRIVAN	4056635	NOV 01, 1998		NCE	OCT 02, 1994
>DLT>	19627 001	PROPOFOL; DIPRIVAN	4056635	NOV 01, 1996		NCE	OCT 02, 1994
	10929 001	SODIUM IODIDE, I-131; IODOTOPE	4349529	SEP 14, 1999			
	10929 002	SODIUM IODIDE, I-131; IODOTOPE	4349529	SEP 14, 1999			
	10929 003	SODIUM IODIDE, I-131; IODOTOPE	4349529	SEP 14, 1999			
	18333 001	SUCRALFATE; CARAFATE				I-44	MAY 11, 1993
	17376 001	SULFAMETHOXAZOLE; SEPTRA	4209513	JUN 24, 1997		I-49	JUN 15, 1993
	17376 002	SULFAMETHOXAZOLE; SEPTRA DS	4209513	JUN 24, 1997		I-49	JUN 15, 1993
	17377 001	SULFAMETHOXAZOLE; BACTRIM				I-49	JUN 15, 1993
	17377 002	SULFAMETHOXAZOLE; BACTRIM DS				I-49	JUN 15, 1993
	17560 001	SULFAMETHOXAZOLE; BACTRIM				I-49	JUN 15, 1993
	17560 002	SULFAMETHOXAZOLE; BACTRIM PEDIATRIC				I-49	JUN 15, 1993
	17598 001	SULFAMETHOXAZOLE; SEPTRA				I-49	JUN 15, 1993
	17598 002	SULFAMETHOXAZOLE; SEPTRA GRAPE				I-49	JUN 15, 1993
	17970 001	TAMOXIFEN CITRATE; NOLVADEX	4536516	AUG 20, 2002		I-50	JUN 21, 1993
	18107 001	TECHNETIUM TC-99M MEDRONATE KIT; MDP-SQUIBB	4115541	SEP 19, 1995			
	19882 001	TECHNETIUM TC-99M MERTIATIDE KIT; TECHNESCAN MAG3				NCE	JUN 15, 1995
	17339 001	TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR; MINITEC	4041317	AUG 09, 1994			
			3920995	NOV 18, 1992			
	18017 001	TIMOLOL MALEATE; BLOCADREN				I-41	MAR 03, 1993
	18017 002	TIMOLOL MALEATE; BLOCADREN				I-41	MAR 03, 1993
	18017 004	TIMOLOL MALEATE; BLOCADREN				I-41	MAR 03, 1993
	19614 001	VERAPAMIL HYDROCHLORIDE; VERELAN	4863742	SEP 05, 2006	U-3	NDF	MAY 29, 1993
	19614 002	VERAPAMIL HYDROCHLORIDE; VERELAN	4863742	SEP 05, 2006	U-3	NDF	MAY 29, 1993
	19655 001	ZIDOVUDINE; RETROVIR	4837208	FEB 02, 2005			
			4833130	FEB 02, 2005		I-47	MAY 02, 1993
			4828838	FEB 02, 2005		ODE	MAR 19, 1994
			4724232	FEB 02, 2005		NCE	MAR 19, 1992
	19910 001	ZIDOVUDINE; RETROVIR	4837208	FEB 02, 2005			
			4833130	FEB 02, 2005		ODE	MAR 19, 1994
			4818538	FEB 02, 2005		I-47	MAY 02, 1993
			4724232	FEB 02, 2005		NCE	MAR 19, 1992
	19951 001	ZIDOVUDINE; RETROVIR	4837208	FEB 02, 2005			
			4833130	FEB 02, 2005		NCE	MAR 19, 1992
			4818538	FEB 02, 2005			
			4724232	FEB 02, 2005		ODE	MAR 19, 1994